<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2408222544
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Varlin
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VARENICLINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        209.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Aurobindo Pharma Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 3103]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N07BA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Varlin contains the active substance varenicline. Varlin is a medicine which is used in adults to help them stop smoking.</p><p dir="ltr">Varlin can help to relieve the craving and withdrawal symptoms associated with stopping smoking.</p><p dir="ltr">Varlin can also reduce the enjoyment of cigarettes if you do smoke when on treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Varlin: </strong></p><p dir="ltr">- If you are allergic to varenicline or any of the other ingredients of this medicine (listed in section 6)</p><p dir="ltr"><strong>Warnings and precautions </strong></p><p dir="ltr">Talk to your doctor or pharmacist before taking Varlin.</p><p dir="ltr">There have been reports of depression, suicidal ideation and behaviour and suicide attempts in patients taking Varlin. If you are taking Varlin and develop agitation, depressed mood, changes in behaviour that are of concern to you or your family or if you develop suicidal thoughts or behaviours you should stop taking Varlin and contact your doctor immediately for treatment assessment.</p><p dir="ltr"><em>The effects of stopping smoking</em></p><p dir="ltr">The effects of changes in your body resulting from stopping smoking, with or without treatment with Varlin, may alter the way other medicines work. Therefore, in some cases an adjustment of the dose may be necessary. See below under &lsquo;Other medicines and Varlin&rsquo; for further details.</p><p dir="ltr">For some people, stopping smoking with or without treatment has been associated with an increased risk of experiencing changes in thinking or behaviour, feelings of depression and anxiety and can be associated with a worsening of psychiatric disorder. If you have a history of psychiatric disorder you should discuss this with your doctor.</p><p dir="ltr"><em>Heart symptoms</em></p><p dir="ltr">New or worse heart or blood vessel (cardiovascular) problems have been reported primarily in people who already have cardiovascular problems. Tell your doctor if you have any changes in symptoms during treatment with Varlin. Get emergency medical help right away if you have symptoms of a heart attack or stroke.</p><p dir="ltr"><em>Seizures</em></p><p dir="ltr">Tell your doctor if you have experienced seizures or have epilepsy before your start Varlin treatment. Some people have reported seizures while taking Varlin.</p><p dir="ltr"><em>Hypersensitivity reactions</em></p><p dir="ltr">Stop taking Varlin and tell your doctor immediately if you experience any of the following signs and symptoms that may indicate a serious allergic reaction: swelling of the face, lips, tongue, gums, throat or body and/or difficulty breathing, wheezing.</p><p dir="ltr"><em>Skin reactions</em></p><p dir="ltr">Potentially life-threatening skin rashes (Stevens-Johnson syndrome and Erythema Multiforme) have been reported with the use of Varlin. If you develop a rash or if your skin starts to peel or blister you should stop taking Varlin and seek emergency medical help.</p><p dir="ltr"><strong>Children and adolescents</strong></p><p dir="ltr">Varlin is not recommended for use in paediatric patients as efficacy was not demonstrated.</p><p dir="ltr"><strong>Other medicines and Varlin</strong></p><p dir="ltr">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p dir="ltr">In some cases as a result of stopping smoking, with or without Varlin, an adjustment of the dose of other medicines may be necessary. Examples include theophylline (a medicine to treat breathing problems), warfarin (a medicine to reduce blood clotting), and insulin (a medicine to treat diabetes). If in doubt, you should consult your doctor or pharmacist.</p><p dir="ltr">If you have severe kidney disease you should avoid taking cimetidine (a medicine used for gastric problems) at the same time as Varlin as this may cause increased blood levels of Varlin.</p><p dir="ltr"><em>Use of Varlin with other therapies for smoking cessation</em></p><p dir="ltr">Consult your doctor before using Varlin in combination with other smoking cessation therapies.</p><p dir="ltr"><strong>Varlin</strong><strong> with food and drink</strong></p><p dir="ltr">There have been some reports of increased intoxicating effects of alcohol in patients taking Varlin. However, it is not known if Varlin actually increases alcohol intoxication.</p><p dir="ltr"><strong>Pregnancy</strong><strong> and breast-feeding</strong></p><p dir="ltr">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p dir="ltr">It is preferable to avoid the use of Varlin while you are pregnant. Talk to your doctor if you are intending to become pregnant.</p><p dir="ltr">Although it was not studied, Varlin may pass into breast milk. You should ask your doctor or pharmacist for advice before taking Varlin.</p><p dir="ltr"><strong>Driving</strong><strong> and using machines</strong></p><p dir="ltr">Varlin may be linked with dizziness, sleepiness and transient loss of consciousness. You should not drive, operate complex machinery or engage in any other potentially hazardous activities until you know whether this medicine affects your ability to perform these activities.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p dir="ltr">You are more likely to stop smoking if you are motivated to stop. Your doctor and pharmacist can provide advice, support and sources of further information to help ensure your attempt to stop smoking is successful.</p><p dir="ltr">Before starting your course of Varlin you should usually decide on a date in the second week of treatment (between day 8 and day 14) when you will stop smoking. If you are not willing or able to set a target quit date within 2 weeks, you may choose your own target quit date within 5 weeks after starting treatment. You should write this date on the pack as a reminder.</p><p dir="ltr">Varlin comes as a white tablet (0.5 mg) and a light blue tablet (1 mg). You start with the white tablet and then usually go to the light blue tablet. See the chart below for the usual dosing instructions which you should follow from Day 1.</p><p dir="ltr">&nbsp;</p><table border="1" align="left" cellspacing="1" cellpadding="1" style="width:493px"><tbody><tr><td style="width:417px"><strong>Dose</strong></td><td style="width:74px"><strong>Week 1</strong></td></tr><tr><td dir="ltr" style="width:417px">From day 1 to day 3, you should take one white Varlin 0.5 mg film-coated tablet once a day.</td><td dir="ltr" style="width:74px">Day 1 - 3</td></tr><tr><td dir="ltr" style="width:417px">From day 4 to day 7, you should take one white Varlin 0.5 mg film-coated tablet twice daily, once in the morning and once in the evening, at about the same time each day.</td><td style="width:74px">Day 4 - 7</td></tr></tbody></table><p dir="ltr" style="margin-left:400px">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><table border="1" align="left" cellspacing="1" cellpadding="1" style="width:498px"><tbody><tr><td style="width:417px"><strong>Dose</strong></td><td style="width:77px"><strong>Week 2</strong></td></tr><tr><td dir="ltr" style="width:417px">From day 8 to day 14 ,&nbsp;you should take one light blue Varlin 1 mg film-coated tablet twice daily, once in the morning&nbsp;and once in the evening, at about the same time each day.</td><td dir="ltr" style="width:77px">Day 8 - 14</td></tr><tr><td dir="ltr" style="width:417px">&nbsp;</td><td style="width:77px">&nbsp;</td></tr></tbody></table><p dir="ltr" style="margin-left:400px">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><table border="1" align="left" cellspacing="1" cellpadding="1" style="width:498px"><tbody><tr><td style="width:417px"><strong>Dose</strong></td><td style="width:77px"><strong>Week 3 -12</strong></td></tr><tr><td dir="ltr" style="width:417px">From day 15 until the end of treatment, you should take one light blue Varlin 1 mg film coated tablet twice daily, once in the morning and once in the evening, at about the same time each day.</td><td dir="ltr" style="width:77px">Day 15 - end of treatment</td></tr><tr><td dir="ltr" style="width:417px">&nbsp;</td><td style="width:77px">&nbsp;</td></tr></tbody></table><p dir="ltr" style="margin-left:400px">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">After 12 weeks of treatment, if you have stopped smoking, your doctor may recommend an additional 12 weeks of treatment with Varlin 1 mg film-coated tablets twice daily to help avoid returning back to smoking.</p><p dir="ltr">If you are not able or willing to quit smoking straight away, you should reduce smoking during the first 12 weeks of treatment and quit by the end of that treatment period. You should then continue to take Varlin 1 mg film-coated tablets twice daily for a further 12 weeks resulting in a total of 24 weeks of treatment.</p><p dir="ltr">Should you experience adverse effects that you cannot tolerate your doctor may decide to reduce your dose temporarily or permanently to 0.5 mg twice daily.</p><p dir="ltr">If you have problems with your kidneys, you should speak to your doctor before taking Varlin. You may need a lower dose.</p><p dir="ltr">Varlin is for oral use.</p><p dir="ltr">The tablets should be swallowed whole with water and can be taken with or without food.</p><p dir="ltr"><strong>If you take more Varlin than you should</strong></p><p dir="ltr">If you accidentally take more Varlin than your doctor prescribed, you must seek medical advice or go to the nearest hospital casualty department immediately. Take your box of tablets with you.</p><p dir="ltr"><strong>If you forget to take Varlin</strong></p><p dir="ltr">Do not take a double dose to make up for a forgotten tablet. It is important that you take Varlin regularly at the same time each day. If you forget to take a dose, take it as soon as you remember. If, it is within 3-4 hours before your next dose, do not take the tablet that you have missed.</p><p dir="ltr"><strong>If you stop taking Varlin</strong></p><p dir="ltr">It has been shown in clinical trials that taking all doses of your medicine at the appropriate times and for the recommended duration of treatment described above will increase your chances of stopping smoking. Therefore, unless your doctor instructs you to stop treatment, it is important to keep taking &nbsp;Varlin, according to the instructions described in the table above.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In smoking cessation therapy, risk of returning to smoking may be elevated in the period immediately following the end of treatment. You may temporarily experience increased irritability, urge to smoke, depression and/or sleep disturbances when you stop taking Varlin. Your doctor may decide to gradually lower your dose of Varlin at the end of treatment.</p><p dir="ltr">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p dir="ltr">Giving up smoking with or without treatment can cause various symptoms. These could include changes of mood (like feeling depressed, irritable, frustrated or anxious), sleeplessness, difficulty concentrating, decreased heart rate and increased appetite or weight gain.</p><p dir="ltr">You should be aware of the possible emergence of serious neuropsychiatric symptoms, such as agitation, depressed mood, or changes in behaviour during a quit attempt with or without Varlin and you should contact a doctor or pharmacist if you experience such symptoms.</p><p dir="ltr">Serious side effects of either an uncommon or rare frequency have occurred in people attempting to quit smoking with Varlin: seizure, stroke, heart attack, suicidal thoughts, loss of contact with reality and unable to think or judge clearly (psychosis), changes in thinking or behaviour (such as aggression and abnormal behaviour). There have also been reports of severe skin reactions including Erythema Multiforme (a type of rash) and Stevens - Johnson Syndrome (a serious illness with blistering of the skin, mouth, around the eyes or genitals) and serious allergic reactions including angioedema (swelling of the face, mouth, or throat).</p><p dir="ltr"><strong>Very common: may affect more than 1 in 10 people</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the nose and throat, abnormal dreams, difficulty sleeping, headache,</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p dir="ltr"><strong>Common: may affect up to 1 in 10 people</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest infection, inflammation of the sinuses</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased weight, decreased appetite, increased appetite</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness, dizziness, changes in the way things taste</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath, cough</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heartburn, vomiting, constipation, diarrhoea, feeling bloated, abdominal pain, toothache, indigestion, flatulence, dry mouth</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash, itching</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint ache, muscle ache, back pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain, tiredness</p><p dir="ltr"><strong>Uncommon: may affect up to 1 in 100 people</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infection, viral infection</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling of panic, difficulty thinking, restlessness, mood swings, depression, anxiety, hallucinations, changes in sex drive</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizure, tremor, feeling sluggish, less sensitive to touch</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conjunctivitis, eye pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringing in the ears</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Angina, rapid heart rate, palpitations, increased heart rate</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood pressure, hot flush</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of nose, sinuses and throat, congestion of nose, throat and chest, hoarseness, hay fever, throat irritation, congested sinuses, excess mucous from nose causing cough, runny nose</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red blood in stools, irritated stomach, change of bowel habit, belching, mouth ulcers, pain in the gums</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reddening of the skin, acne, increased sweating, night sweats</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle spasms, chest wall pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormally frequent urination, urination at night</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased menstrual flow</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest discomfort, flu like illness, fever, feeling weak or unwell</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood sugar</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart attack</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suicidal thoughts</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in thinking or behaviour (such as aggression)</p><p dir="ltr"><strong>Rare: may affect up to 1 in 1,000 people</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive thirst</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling unwell or unhappy, slow thinking</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stroke</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased muscle tension, difficulty with speech, difficulty with coordination, reduced sense of taste, altered sleep pattern</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disturbed vision, eyeball discolouration, dilated pupils, sensitivity to light, shortsightedness, watery eyes</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heart beat or heart rhythm disturbances</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Throat pain, snoring</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in vomit, abnormal stools, coated tongue</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stiff joints, rib pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glucose in urine, increased urine volume and frequency</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaginal discharge, changes in sexual ability</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling cold, cyst</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleep walking</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of contact with reality and unable to think or judge clearly (psychosis)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal behaviour</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe skin reactions including Erythema Multiforme (a type of rash) and Stevens-Johnson Syndrome (a serious illness with blistering of the skin, mouth, around the eyes or genitals)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious allergic reactions including angioedema (swelling of the face, mouth, or throat)</p><p dir="ltr"><strong>Not known</strong></p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transient loss of consciousness</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the reach and sight of children.</p><p dir="ltr">Do not use this medicine after the expiry date stated on the blister or carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p dir="ltr">Store below 30&deg;C.</p><p dir="ltr">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substance is Varenicline tartrate.</p><p dir="ltr">Each tablet contains 0.85 mg Varenicline tartrate Equivalent to 0.5 mg of Varenicline.</p><p dir="ltr">Each tablet contains 1.71 mg Varenicline tartrate Equivalent to 1.0 mg of Varenicline.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">The other ingredients are:</p><p dir="ltr"><em>Tablet core:</em> Cellulose, Microcrystalline (PH-101), Cellulose, Microcrystalline (PH-102), Calcium Hydrogen Phosphate Anhydrous, Croscarmellose Sodium, Silica Colloidal Anhydrous, Magnesium Stearate and Purified water.</p><p dir="ltr"><em>Tablet coating:</em></p><p dir="ltr">0.5 mg: Opadry Complete Film Coating System 03A58900 White material (RMO419) (contains Hypromellose 2910 E464 and Titanium Dioxide E171).</p><p dir="ltr">1 mg: Opadry Complete Film Coating System 03A505012 Blue (contains Hypromellose 2910 E464, Titanium Dioxide E171, FD&amp;C BLUE #2/Indigo carmine aluminum E132, FD&amp;C BLUE #2/Indigo carmine aluminum lake E132).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                0.5 mg: Capsular, biconvex, white, film coated tablets, approximately 8 x 4 mm debossed with ‘VA’ on one side and ‘0.5’ on the other side.
1 mg: Capsular, biconvex, light blue, film coated tablets, approximately 10 x 5 mm debossed with ‘VA’ on one side and ‘1’ on the other side. 

Varlin available in in clear PVC- Aluminium blister pack.
-	Treatment initiation pack: 11’s x 0.5 mg (11’s blister x 1) and 14’s x 1 mg (14’s blister x 1).
-	Follow-on (maintenance) pack: 56’s x 1 mg (14’s blister x 4) 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Manufacturer:</strong></p><p dir="ltr">Aurobindo Pharma Limited,</p><p dir="ltr">Unit-X, Plot No.16, APIIC Multi Products SEZ,</p><p dir="ltr">Menakuru Village, Naidupeta Mandal,</p><p dir="ltr">S.P.S.R. Nellore District,</p><p dir="ltr">Andhra Pradesh, India.</p><p dir="ltr"><strong>Marketing Authorization Holder:</strong></p><p dir="ltr">Aurobindo Pharma Saudi Arabia Limited,</p><p dir="ltr">Jeddah, Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 09/2020, version number is 00.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي فارلين على المادة الفعالة فارينيكلين، وفارلين دواء يُستخدم مع البالغين لمساعدتهم على التوقف عن التدخين.</p><p dir="RTL">&nbsp;يُمكن لفارلين أن يساعد في تخفيف أعراض الرغبة والانسحاب المتزامنة مع التوقف عن التدخين.</p><p dir="RTL">&nbsp;يُمكن لفارلين أيضًا خفض التمتع بالسجائر إن قمت بالتدخين أثناء العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ فارلين:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه فارينيكلين أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6)</p><p dir="RTL"><strong>&nbsp;التحذيرات والاحتياطات</strong></p><p dir="RTL">&nbsp;تحدث مع طبيبك أو الصيدلي قبل أخذ فارلين.</p><p dir="RTL">&nbsp;أُبلغ عن حدوث اكتئاب وأفكار وسلوك انتحاري ومحاولات للانتحار مع المرضى الذين يأخذون فارلين. إن كنت تأخذ فارلين وعانيت من التهيج أو المزاج المكتئب أو تغيرات بالسلوك من شأنها إثارة مخاوفك أو مخاوف عائلتك، أو إن عانيت من أفكار أو سلوك انتحاري، يجب عليك حينئذ أن تتوقف عن أخذ فارلين وتتواصل مع الطبيب على الفور لتقييم العلاج.</p><p dir="RTL"><em>تأثير التوقف عن التدخين</em></p><p dir="RTL">قد تؤدي تأثيرات التغيرات الحادثة بجسدك، والناجمة عن التوقف عن التدخين، سواء كُنت تُعالج بفارلين أو لا، إلى تغيير كيفية عمل الأدوية الأخرى. ولذلك، قد تكون هناك حاجة في بعض الحالات إلى تعديل الجرعة. انظر أدناه تحت &quot;الأدوية الأخرى وفارلين&quot; للمزيد من التفاصيل.</p><p dir="RTL">تعلق التوقف عن التدخين عند بعض الأشخاص، مع العلاج أو بدونه، بزيادة خطر حدوث تغيرات بالتفكير أو السلوك والشعور بالاكتئاب والقلق، وقد يرتبط بتفاقم الاضطرابات النفسية. إن كنت مصابًا من قبل باضطرابات نفسية، يجب أن تناقش ذلك مع طبيبك.</p><p dir="RTL"><em>أعراض القلب</em></p><p dir="RTL">أُبلغ عن تفاقم المشاكل القلبية أو الوعائية (قلبية وعائية)، أو حدوث مشاكل جديدة بصورة أساسية لدي الأشخاص الذين يعانون بالفعل من مشاكل قلبية وعائية. أعلم طبيبك إن كنت تعاني من اي تغيرات بالأعراض أثناء العلاج بفارلين، والجأ لمساعدة الطوارئ الطبية على الفور إن عانيت من أعراض الأزمة القلبية أو السكتة الدماغية.</p><p dir="RTL"><em>النوبات</em></p><p dir="RTL">أعلم الطبيب إن عانيت من نوبات أو كنت مصابًا بالصرع قبل بدء العلاج بفارلين، حيث أبلغ بعض الأشخاص عن حدوث نوبات أثناء أخذ فارلين.</p><p dir="RTL">تفاعلات فرط الحساسية</p><p dir="RTL">توقف عن أخذ فارلين وأعلم الطبيب على الفور إن عانيت من أي من العلامات والأعراض التالية التي قد تدل على تفاعل تحسسي خطير: تورم الوجه أو الشفتين أو اللسان او اللثة أو الحلق أو الجسم و/أو صعوبة التنفس أو الأزيز.</p><p dir="RTL"><em>التفاعلات الجلدية</em></p><p dir="RTL">أُبلغ عن حدوث طفح جلدي قد يهدد الحياة (متلازمة ستيفنز-جونسون والحمامي متعدد الأشكال) أثناء استخدام فارلين. إن عانيت من طفح أو بدأ جلدك في التقشر او التبثر، يجب أن تتوقف عن أخذ فارلين وتطلب مساعدة الطوارئ الطبية.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوصى باستعمال فارلين مع الأطفال المرضى حيث لم تُدرس فعاليته.</p><p dir="RTL"><strong>الأدوية الأخرى وفارلين</strong></p><p dir="RTL">أعلم طبيبك إن كنت تأخذ أو أخذت حديثًا أو قد تأخذ أي أدوية أخرى.</p><p dir="RTL">قد تكون هناك حاجة في بعض الحالات لتعديل جرعة الأدوية الأخرى كنتيجة للتوقف عن التدخين، وذلك مع فارلين أو بدونه. تتضمن الأمثلة ثيوفيللين (دواء لعلاج المشاكل التنفسية) ووارفارين (دواء لخفض التخثر الدموي) وإنسولين (دواء لعلاج السكري). يجب أن تستشير طبيبك أو الصيدلي في حالة الشك.</p><p dir="RTL">إن كنت تعاني من مرض كلوي حاد، يجب أن تتجنب أخذ سيميتيدين (دواء للمشاكل المعدية) في نفس الوقت مع فارلين، فقد يتسبب ذلك في ارتفاع مستويات فارلين في الدم.</p><p dir="RTL"><em>استخدام فارلين مع العلاجات الأخرى للإقلاع عن التدخين</em></p><p dir="RTL">استشر طبيبك قبل استخدام فارلين بالتزامن مع العلاجات الأخرى للإقلاع عن التدخين.</p><p dir="RTL"><strong>فارلين مع الطعام والشراب</strong></p><p dir="RTL">توجد بعض التقارير حول زيادة التأثيرات السامة للكحول مع المرضى الذين يأخذون فارلين. وفي جميع الاحوال، من غير المعلوم إن كان فارلين يتسبب بالفعل في زيادة السمية الكحولية.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملًا أو تقومين بالإرضاع، أو يُحتمل أن تصبحين حاملًا أو تخططين لإنجاب طفل، يجب عليكِ أخذ مشورة طبيبك أو الصيدلي قبل استعمال هذا الدواء.</p><p dir="RTL">يُفضل تجنب استعمال فارلين أثناء الحمل. تحدثي مع طبيبك إن كنتِ ترغبين في الحمل.</p><p dir="RTL">قد يمر فارلين إلى حليب الثدي، بالرغم من عدم دراسة ذلك. ل يجب عليكِ أخذ مشورة طبيبك أو الصيدلي قبل استعمال فارلين.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يرتبط فارلين بالدوخة والنعاس وفقدان الوعي المؤقت. يجب عدم القيادة أو تشغيل الآلات المعقدة أو الانغماس في الأنشطة الأخرى المحتمل خطورتها حتى تعلم إن كان هذا المنتج الطبي يؤثر على قدرتك على أداء هذه الأنشطة أم لا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">خذ هذا الدواء دائمًا كما أخبرك طبيبك، وتحقق من طبيبك أو الصيدلي إن لم تكن متأكدًا.</p><p dir="RTL">تزداد احتمالية توقفك عن التدخين إن كان هناك دافعًا للتوقف. يُمكن للطبيب والصيدلي توفير النصح والدعم ومصادر المعلومات الإضافية للمساعدة في تأكيد نجاح محاولتك للتوقف عن التدخين.</p><p dir="RTL">قبل بدء برنامج العلاج بفارلين، يجب عادة أن تحدد يومًا في الأسبوع الثاني من العلاج (ما بين اليوم 8 واليوم 14) ستتوقف فيه عن التدخين. إن لم يكن في نيتك أو تستطيع تحديد يوم للإقلاع خلال أسبوعين، يُمكنك اختيار يوم الإقلاع خلال 5 أسابيع بعد بدء العلاج. يجب أن تكتب هذا اليوم على ظهر مفكرة.</p><p dir="RTL">يأتي فارلين في صورة قرص أبيض (0.5 مجم) وقرص أزرق فاتح (1 مجم). ستبدأ بالقرص الأبيض وبعدها ستنتقل عادة للقرص الأزرق الفاتح. انظر الجدول أدناه لتعليمات الجرعة المعتادة التي يجب أن تتبعها بدءًا من اليوم 1.</p><p dir="RTL">&nbsp;</p><table border="1" align="right" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:92px"><strong>الأسبوع 1</strong></td><td style="width:406px"><strong>الجرعة</strong></td></tr><tr><td style="width:92px">اليوم 1 - 3</td><td style="width:406px">من اليوم 1 إلى اليوم 3، يجب أن تأخذ قرص واحد أبيض مغلف من فارلين 0.5 مجم مرة واحدة يوميًا.</td></tr><tr><td style="width:92px">اليوم 4 - 7</td><td style="width:406px">من اليوم 4 إلى اليوم 7، يجب أن تأخذ قرص واحد أبيض مغلف من فارلين 0.5 مجم مرتان يوميًا، مرة في الصباح وأخرى في المساء، في نفس الوقت تقريبًا كل يوم.</td></tr></tbody></table><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:659px"><tbody><tr><td><p dir="RTL">&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:85px"><strong>الأسبوع 2</strong></td><td style="width:413px"><strong>الجرعة</strong></td></tr><tr><td style="width:85px">اليوم 8 &ndash; 14</td><td style="width:413px">من اليوم 8 إلى اليوم 14، يجب أن تأخذ قرص واحد أزرق فاتح مغلف من فارلين 1 مجم مرتان يوميًا، مرة في الصباح وأخرى في المساء، في نفس الوقت تقريبًا كل يوم.</td></tr></tbody></table><p>&nbsp;</p></td></tr><tr><td><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:84px">الأسابيع 3 - 12</td><td style="width:414px"><strong>الجرعة</strong></td></tr><tr><td style="width:84px">اليوم 15 - نهاية العلاج</td><td style="width:414px">من اليوم 15 حتى نهاية العلاج، يجب أن تأخذ قرص واحد أزرق فاتح مغلف من فارلين 1 مجم مرتان يوميًا، مرة في الصباح وأخرى في المساء، في نفس الوقت تقريبًا كل يوم.</td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p><span style="text-align:unset">&nbsp; &nbsp;بعد 12 أسبوع من العلاج، إن توقفت عن التدخين، ربما يوصي الطبيب بـ 12 أسبوع إضافي من العلاج بأقراص فارلين المغلفة 1 مجم مرتان يوميًا لتجنب العودة للتدخين.</span></p><p dir="RTL">إن لم تستطع أو ترغب في التوقف عن التدخين مباشرة، يجب أن تُخفض وتيرة التدخين خلال الأسابيع 12 الأولى من العلاج، وتتوقف بنهاية هذه المدة العلاجية. يجب بعد ذلك أن تستمر في أخذ أقراص فارلين المغلفة مرتان يوميًا لـ 12 أسبوع إضافية، الأمر الذي ينتج عنه 24 أسبوعًا إجماليًا من العلاج.</p><p dir="RTL">في حالة معاناتك من آثار سلبية لا تستطيع تحملها، قد يرغب الطبيب في خفض جرعتك مؤقتًا أو دائمًا لـ 0.5 مجم مرتان يوميًا.</p><p dir="RTL">إن كنت مصابًا بمشاكل في الكلى، يجب أن تتحدث مع طبيبك قبل أخذ فارلين، فقد تحتاج لجرعة أقل.</p><p dir="RTL">فارلين للاستعمال الفموي.</p><p dir="RTL">يجب بلع الأقراص كاملة مع كوب من الماء، ويمكن أخذه مع الطعام أو بدونه.</p><p dir="RTL"><strong>إذا أخذت أكثر مما يجب من فارلين</strong></p><p dir="RTL">إن أخذت من فارلين عن طريق الخطأ أكثر مما وصف الطبيب، يجب أن تلجأ للمشورة الطبية أو تذهب لقسم الإصابات في أقرب مستشفى على الفور. خذ علبة الأقراص معك.</p><p dir="RTL"><strong>إذا نسيت تناول فارلين</strong></p><p dir="RTL">لا تأخذ جرعة مزدوجة للتعويض عن القرص المنسي. ومن المهم أن تأخذ فارلين بانتظام في نفس الموعد كل يوم. إذا نسيت أخذ جرعة، خذها بمجرد تذكرك. وإن تذكرت خلال 3-4 ساعات قبل الجرعة التالية، فلا تأخذ القرص الذي نسيته.</p><p dir="RTL"><strong>إذا توقفت عن أخذ فارلين</strong></p><p dir="RTL">ظهر من خلال الدراسات الإكلينيكية أن أخذ جميع جرعات الدواء في الموعد المحدد ولفترة العلاج الموصي بها المذكورة أعلاه سيزيد من فرص التوقف عن التدخين. وبالتالي، مالم يطلب منك الطبيب إيقاف العلاج، من المهم أن تستمر في أخذ فارلين طبقًا للتعليمات المذكورة في الجدول أعلاه.</p><p dir="RTL">خلال علاج الإقلاع عن التدخين، قد يرتفع خطر العودة للتدخين خلال الفترة التالية لنهاية العلاج مباشرة. قد تعاني مؤقتًا من زيادة التهيج والرغبة في التدخين والاكتئاب واضطرابات النوم عند التوقف عن أخذ فارلين. قد يقرر الطبيب خفض جرعة فارلين تدريجيًا في نهاية العلاج.</p><p dir="RTL">تحدث مع طبيبك أو الصيدلي إن كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يتسبب هذا الدواء بآثار جانبية، بالرغم من عدم إصابة الجميع بها.</p><p dir="RTL">قد يتسبب الإقلاع عن التدخين، مع العلاج أو بدونه، في أعراض مختلفة. وقد تتضمن تغيرات بالمزاج (مثل الشعور بالاكتئاب أو التهيج أو التوتر أو القلق) والأرق وصعوبة التركيز وانخفاض معدل نبض القلب وزيادة الشهية وزيادة الوزن.</p><p dir="RTL">يجب أن تكون على علم باحتمالية ظهور أعراض نفسية عصبية، مثل التهيج أو المزاج المكتئب أو تغيرات السلوك، أثناء محاولة التوقف مع فارلين أو بدونه، كما يجب أن تتواصل مع الطبيب أو الصيدلي إن عانيت من مثل تلك الأعراض.</p><p dir="RTL">حدثت آثار جانبية خطيرة ذات تكرارية غير شائعة أو نادرة مع الأشخاص الذين يحاولون الإقلاع عن التدخين مع فارلين: نوبات، سكتة دماغية، أزمة قلبية، أفكار انتحارية، فقدان التواصل مع الواقع وعدم القدرة على التفكير أو الحكم بوضوح (ذهان)، تغيرات بالتفكير أو السلوك (مثل العنف والسلوك غير الطبيعي). كما أُبلغ عن حدوث تفاعلات جلدية شديدة تتضمن الحمامي متعدد الأشكال (نوع من الطفح) ومتلازمة ستيفنز-جونسون (مرض خطير يسبب تبثر الجلد أو الفم أو ما حول العينين أو الأعضاء التناسلية) وتفاعلات تحسسية خطيرة تتضمن الوذمة الوعائية (تورم الوجه أو الفم أو الحلق).</p><p dir="RTL"><strong>شائعة جدًا: قد تؤثر على أكثر من 1 لكل 10 أشخاص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنف والحلق، أحلام غير طبيعية، صعوبة في النوم، صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL"><strong>شائعة: قد تؤثر على 1 لكل 10 أشخاص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الصدر، التهاب الجيوب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن، انخفاض الشهية، زيادة الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس، دوخة، تغيرات في مذاق الأشياء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة بالتنفس، سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة بالمعدة، قيء، إمساك، إسهال، شعور بالانتفاخ، ألم بالبطن، عسر هضم، انتفاخ، جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، حكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل، ألم بالعضلات، ألم بالظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر، إرهاق</p><p dir="RTL"><strong>غير شائعة: قد تؤثر على 1 لكل 100 شخص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فطرية، عدوى فيروسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالهلع، صعوبة التفكير، إرهاق، تغيرات مزاجية، اكتئاب، تهيج، هلوسة، تغيرات بالدافع الجنسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات، ارتعاش، شعور بالخمول، انخفاض الحساسية تجاه اللمس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الملتحمة، ألم بالعينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين في الأذنين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ذبحة صدرية، سرعة نبض القلب، خفقان، زيادة نبض القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم، دفق ساخن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنف والجيوب والحلق، احتقان الأنف والحلق والصدر، بحة الصوت، تهيج الحلق، احتقان الجيوب، مخاط زائد من الأنف يتسبب في السعال، سيلان الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دماء حمراء بالبراز، تهيج المعدة، تغيرات بعادات الأمعاء، تجشؤ، قرح الفم، ألم باللثة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد، بثور، زيادة التعرق، عرق ليلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات عضلية، ألم بجدار الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبول متكرر غير معتاد، تبول ليلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة تدفق الحيض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب الصدر، مرض شبيه بالبرد، حمى، شعور بالضعف أو الإعياء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى السكر بالدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزمة قلبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار انتحارية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات بالأفكار أو السلوك (مثل العنف)</p><p dir="RTL"><strong>نادرة: قد تؤثر على 1 لكل 1,000 شخص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عطش شديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء أو الحزن، بطء التفكير</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكتة دماغية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة توتر العضلات، صعوبة التحدث، صعوبة تجاه الاتزان، انخفاض الإحساس بالتذوق، تغير نمط النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب الرؤية، تغير لون كرة العين، حساسية تجاه الضوء، قصر النظر، دموع العينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبض قلب غير منتظم أو اضطرابات نظم القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الحلق، شخير</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء دموي، براز غير طبيعي، تغلف اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس المفاصل، آلام الضلوع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلوكوز بالبول، زيادة حجم البول وتكراريته</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إفرازات مهبلية، تغيرات بالقدرة الجنسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالبرد، تكيس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشي أثناء النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الاتصال بالواقع وعدم القدرة على التفكير والحكم بوضوح (ذهان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سلوك غير معتاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية شديدة تتضمن الحمامي متعدد الأشكال (نوع من الطفح) ومتلازمة ستيفنز-جونسون (مرض خطير يصاحبه تبثر في الجلد أو الفم أو ما حول العينين أو الأعضاء التناسلية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية خطيرة تتضمن الوذمة الوعائية (تورم الوجه أو الفم أو الحلق)</p><p dir="RTL"><strong>&nbsp;أعراض غير معلومة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;فقدان مؤقت للوعي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ابق هذا الدواء بعيدا عن نظر الأطفال ومتناول أيديهم.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ الانتهاء المذكور على الشريط أو الكرتون بعد &ldquo;EXP&rdquo;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">يُحفظ تحت 30 درجة مئوية.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق الصرف الصحي أو النفايات المنزلية. واسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه التدابير تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي فارينيكلين تارترات.</p><p dir="RTL">يحتوي كل قرص على 0.85 مجم من فارينيكلين تارترات يكافئ 0.5 مجم من فارينيكلين.</p><p dir="RTL">يحتوي كل قرص على 1.71 مجم من فارينيكلين تارترات يكافئ 1.71 مجم من فارينيكلين.</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL"><em>جسم القرص:</em> سيليولوز دقيق التبلور (PH-101)، سيليولوز دقيق التبلور (PH-102)، فوسفات كالسيوم هيدروجينية لا مائية، كروسكارميلوز صوديوم، سيليكا غروية لا مائية، ستيرات ماغنسيوم، ماء مُقطر.</p><p dir="RTL"><strong>غلاف القرص:</strong></p><p dir="RTL">0.5 مجم: نظام تغليف أوبادري غشائي كامل 03A58900 أبيض (RMO419) (يحتوي على هيبروميلوز 2910 E464 وثاني أكسيد التيتانيوم E171).</p><p dir="RTL">1 مجم: نظام تغليف أوبادري غشائي كامل 03A505012 أزرق (يحتوي على هيبروميلوز 2910 E464 وثاني أكسيد التيتانيوم E171 وFD&amp;C أزرق #2/إنديجو كارمين ألومنيوم E132، FD&amp;C أزرق #2/صبغة إنديجو كارمين ألومنيوم ترسيبية E132).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو فارلين ومحتويات العبوة</strong></p><p dir="RTL"><strong>0.5 مجم:</strong> أقراص كبسولية مغلفة بيضاء ثنائية التحدب، 8 x 4 مم تقريبًا، منقوش على أحد جانبيها &quot;VA&quot; و&quot;0.5&quot; على الجانب الآخر.</p><p dir="RTL"><strong>1 مجم:</strong> أقراص كبسولية مغلفة بيضاء ثنائية التحدب، 10 x 5 مم تقريبًا، منقوش على أحد جانبيها &quot;VA&quot; و&quot;1&quot; على الجانب الآخر.</p><p dir="RTL">&nbsp;أقراص فارلين متاحة في عبوة شرائط شفافة من البولي فينيل كلوريد - ألومنيوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة بدء العلاج: 11 قرص 0.5 مجم (شريط واحد به 11 قرص) و14 قرص 1 مجم (شريط واحد به 14 قرص).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة المتابعة (الحفاظ): 56 قرص 1 مجم (4 شرائط بكل منها 14 قرص)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المُصنع:</strong></p><p dir="RTL">أوروبيندو فارما المحدودة،</p><p dir="RTL">الوحدة - X، قطعة رقم 16، مؤسسة أندهرا براديش للبنية التحتية الصناعية، المنطقة الاقتصادية الخاصة،</p><p dir="RTL">قرية ميناكورو، مقاطعة نيدوبيتا،</p><p dir="RTL">إس بي إس آر. حي نيلور،</p><p dir="RTL">أندهرا براديش، الهند.</p><p dir="RTL"><strong>حامل ترخيص التسويق:</strong></p><p dir="RTL">أوروبيندو فارما السعودية المحدودة،</p><p dir="RTL">جدة، المملكة العربية السعودية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اعتمدت هذه النشرة في 09/2020، رقم الإصدار هو 00.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Varenicline Tablets 
(TRADE) NAME OF THE PRODUCT: Varlin 
 STRENGTH: 0.5 mg & 1 mg

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                0.5 mg:
Each tablet contains 0.85 mg Varenicline tartrate equivalent to 0.5 mg of Varenicline free base.
1 mg:
Each tablet contains 1.71 mg Varenicline tartrate equivalent to 1.0 mg of Varenicline free base.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                0.5 mg: Capsular, biconvex, white, film coated tablets, debossed with ‘VA’ on one side and ‘0.5’ on the other side.
1 mg: Capsular, biconvex, light blue, film coated tablets, debossed with ‘VA’ on one side and ‘1’ on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Varenicline is indicated for smoking cessation in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Posology<br />The recommended dose is 1 mg varenicline twice daily following a 1-week titration as follows:</p><p dir="ltr">Days 1 &ndash; 3:&nbsp;&nbsp; &nbsp;0.5 mg once daily<br />Days 4 &ndash; 7:&nbsp;&nbsp; &nbsp;0.5 mg twice daily<br />Day 8 &ndash; End of treatment:&nbsp;&nbsp; &nbsp;1 mg twice daily</p><p dir="ltr">&nbsp;</p><p dir="ltr">The patient should set a date to stop smoking. Varenicline dosing should usually start at 1-2 weeks before this date (see section 5.1). Patients should be treated with Varenicline for 12 weeks.</p><p dir="ltr">For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks treatment with Varenicline at 1 mg twice daily may be considered for the maintenance of abstinence (see section 5.1).</p><p dir="ltr">A gradual approach to quitting smoking with Varenicline should be considered for patients who are not able or willing to quit abruptly. Patients should reduce smoking during the first 12 weeks of treatment and quit by the end of that treatment period. Patients should then continue taking Varenicline for an additional 12 weeks for a total of 24 weeks of treatment (see section 5.1).</p><p dir="ltr">Patients who are motivated to quit and who did not succeed in stopping smoking during prior Varenicline therapy, or who relapsed after treatment, may benefit from another quit attempt with Varenicline (see section 5.1).</p><p dir="ltr">Patients who cannot tolerate adverse reactions of Varenicline may have the dose lowered temporarily or permanently to 0.5 mg twice daily.</p><p dir="ltr">In smoking cessation therapy, risk for relapse to smoking is elevated in the period immediately following the end of treatment. In patients with a high risk of relapse, dose tapering</p><p dir="ltr">may be considered (see section 4.4).&nbsp;</p><p dir="ltr"><em>Elderly</em></p><p dir="ltr">No dosage adjustment is necessary for elderly patients (see section 5.2). Because elderly patients are more likely to have decreased renal function, prescribers should consider the renal status of an elderly patient.</p><p dir="ltr"><em>Renal impairment</em></p><p dir="ltr">No dosage adjustment is necessary for patients with mild (estimated creatinine clearance &gt; 50 ml/min and &le; 80 ml/min) to moderate (estimated creatinine clearance &ge; 30 ml/min and &le; 50 ml/min) renal impairment.</p><p dir="ltr">For patients with moderate renal impairment who experience adverse reactions that are not tolerable, dosing may be reduced to 1 mg once daily.</p><p dir="ltr">For patients with severe renal impairment (estimated creatinine clearance &lt; 30 ml/min), the recommended dose of Varenicline is 1 mg once daily. Dosing should begin at 0.5 mg once daily for the first 3 days then increased to 1 mg once daily. Based on insufficient clinical experience with Varenicline in patients with end stage renal disease, treatment is not recommended in this patient population (see section 5.2).</p><p dir="ltr"><em>Hepatic impairment</em></p><p dir="ltr">No dosage adjustment is necessary for patients with hepatic impairment (see section 5.2).</p><p dir="ltr"><em>Paediatric population</em></p><p dir="ltr">Varenicline is not recommended for use in paediatric patients because its efficacy in this population was not demonstrated (see sections 5.1 and 5.2).</p><p dir="ltr"><u>Method of administration</u></p><p dir="ltr">Varenicline is for oral use and the tablets should be swallowed whole with water. Varenicline can be taken with or without food</p><p>&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Effect of smoking cessation</u></p><p dir="ltr">Physiological changes resulting from smoking cessation, with or without treatment with Varenicline, may alter the pharmacokinetics or pharmacodynamics of some medicinal products, for which dosage adjustment may be necessary (examples include theophylline, warfarin and insulin). As smoking induces CYP1A2, smoking cessation may result in an increase of plasma levels of CYP1A2 substrates.</p><p dir="ltr"><u>Neuropsychiatric symptoms</u></p><p dir="ltr">Changes in behaviour or thinking, anxiety, psychosis, mood swings, aggressive behaviour, depression, suicidal ideation and behaviour and suicide attempts have been reported in patients attempting to quit smoking with Varenicline in the post-marketing experience.</p><p dir="ltr">A large randomised, double-blind, active and placebo-controlled study was conducted to compare the risk of serious neuropsychiatric events in patients with and without a history of psychiatric disorder treated for smoking cessation with varenicline, bupropion, nicotine replacement therapy patch (NRT) or placebo. The primary safety endpoint was a composite of neuropsychiatric adverse events that have been reported in post-marketing experience.</p><p dir="ltr">The use of varenicline in patients with or without a history of psychiatric disorder was not associated with an increased risk of serious neuropsychiatric adverse events in the composite primary endpoint compared with placebo (see section 5.1 <strong>Pharmacodynamic properties</strong> - <em>Study in Subjects with and without a History of Psychiatric Disorder</em>).</p><p dir="ltr">&nbsp;Depressed mood, rarely including suicidal ideation and suicide attempt, may be a symptom of nicotine withdrawal.</p><p dir="ltr">Clinicians should be aware of the possible emergence of serious neuropsychiatric symptoms in patients attempting to quit smoking with or without treatment. If serious neuropsychiatric symptoms occur whilst on varenicline treatment, patients should discontinue varenicline immediately and contact a healthcare professional for re-evaluation of treatment.</p><p dir="ltr"><u>History of psychiatric disorders</u></p><p dir="ltr">Smoking cessation, with or without pharmacotherapy, has been associated with exacerbation of underlying psychiatric illness (e.g. depression).</p><p dir="ltr">Varenicline smoking cessation studies have provided data in patients with a history of psychiatric disorders (see section 5.1).</p><p dir="ltr">In a smoking cessation clinical trial, neuropsychiatric adverse events were reported more frequently in patients with a history of psychiatric disorders compared to those without a history of psychiatric disorders, regardless of treatment (see section 5.1).</p><p dir="ltr">Care should be taken with patients with a history of psychiatric illness and patients should be advised accordingly.</p><p dir="ltr"><u>Seizures</u></p><p dir="ltr">In clinical trials and post-marketing experience there have been reports of seizures in patients with or without a history of seizures, treated with Varenicline. Varenicline should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.</p><p dir="ltr"><u>Treatment discontinuation</u></p><p dir="ltr">At the end of treatment, discontinuation of Varenicline was associated with an increase in irritability, urge to smoke, depression, and/or insomnia in up to 3% of patients. The prescriber should inform the patient accordingly and discuss or consider the need for dose tapering.</p><p dir="ltr"><u>Cardiovascular events</u></p><p dir="ltr">Patients taking Varenicline should be instructed to notify their doctor of new or worsening cardiovascular symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction or stroke (see section 5.1).</p><p dir="ltr"><u>Hypersensitivity reactions</u></p><p dir="ltr">There have been post-marketing reports of hypersensitivity reactions including angioedema in patients treated with varenicline. Clinical signs included swelling of the face, mouth (tongue, lips, and gums), neck (throat and larynx) and extremities. There were rare reports of life-threatening angioedema requiring urgent medical attention due to respiratory compromise. Patients experiencing these symptoms should discontinue treatment with varenicline and contact a health care provider immediately.</p><p dir="ltr"><u>Cutaneous reactions</u></p><p dir="ltr">There have also been post-marketing reports of rare but severe cutaneous reactions, including St&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; evens - Johnson syndrome and Erythema Multiforme in patients using varenicline. As these skin reactions can be life threatening, patients should discontinue treatment at the first sign of rash or skin reaction and contact a healthcare provider immediately.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Based on varenicline characteristics and clinical experience to date, Varenicline has no clinically meaningful drug interactions. No dosage adjustment of Varenicline or co-administered medicinal products listed below is recommended.</p><p dir="ltr"><em>In vitro</em> studies indicate that varenicline is unlikely to alter the pharmacokinetics of compounds that are primarily metabolised by cytochrome P450 enzymes.</p><p dir="ltr">Furthermore, since metabolism of varenicline represents less than 10% of its clearance, active substances known to affect the cytochrome P450 system are unlikely to alter the pharmacokinetics of varenicline (see section 5.2) and therefore a dose adjustment of Varenicline would not be required.</p><p dir="ltr"><em>In vitro</em> studies demonstrate that varenicline does not inhibit human renal transport proteins at therapeutic concentrations. Therefore, active substances that are cleared by renal secretion (e.g., metformin - see below) are unlikely to be affected by varenicline.</p><p dir="ltr"><u>Metformin</u></p><p dir="ltr">Varenicline did not affect the pharmacokinetics of metformin. Metformin had no effect on varenicline pharmacokinetics.</p><p dir="ltr"><u>Cimetidine</u></p><p dir="ltr">Co-administration of cimetidine, with varenicline increased the systemic exposure of varenicline by 29% due to a reduction in varenicline renal clearance. No dosage adjustment is recommended based on concomitant cimetidine administration in subjects with normal renal function or in patients with mild to moderate renal impairment. In patients with severe renal impairment, the concomitant use of cimetidine and varenicline should be avoided.</p><p dir="ltr"><u>Digoxin</u></p><p dir="ltr">Varenicline did not alter the steady-state pharmacokinetics of digoxin.</p><p dir="ltr"><u>Warfarin</u></p><p dir="ltr">Varenicline did not alter the pharmacokinetics of warfarin. Prothrombin time (INR) was not affected by varenicline. Smoking cessation itself may result in changes to warfarin pharmacokinetics (see section 4.4).</p><p dir="ltr"><u>Alcohol</u></p><p dir="ltr">There are limited clinical data on any potential interaction between alcohol and varenicline. There have been post marketing reports of increased intoxicating effects of alcohol in patients treated with varenicline. A causal relationship between these events and varenicline use has not been established.</p><p dir="ltr"><u>Use with other therapies for smoking cessation</u></p><p dir="ltr"><em>Bupropion</em></p><p dir="ltr">Varenicline did not alter the steady-state pharmacokinetics of bupropion.</p><p dir="ltr"><em>Nicotine replacement therapy</em> <em>(NRT)</em></p><p dir="ltr">When varenicline and transdermal NRT were co-administered to smokers for 12 days, there was a statistically significant decrease in average systolic blood pressure (mean 2.6 mmHg) measured on the final day of the study. In this study, the incidence of nausea, headache, vomiting, dizziness, dyspepsia, and fatigue was greater for the combination than for NRT alone.</p><p dir="ltr">Safety and efficacy of Varenicline in combination with other smoking cessation therapies have not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pregnancy</u></p><p dir="ltr">A moderate amount of data on pregnant women indicated no malformative or foetal/neonatal toxicity of varenicline (see section 5.1).</p><p dir="ltr">Animal studies have shown reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of varenicline during pregnancy (see section 5.1).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Breast-feeding</u></p><p dir="ltr">It is unknown whether varenicline is excreted in human breast milk. Animal studies suggest that varenicline is excreted in breast milk. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Varenicline should be made taking into account the benefit of breast-feeding to the child and the benefit of Varenicline therapy to the woman.</p><p dir="ltr"><u>Fertility</u></p><p dir="ltr">There are no clinical data on the effects of varenicline on fertility.</p><p dir="ltr">Non-clinical data revealed no hazard for humans based on standard male and female fertility studies in the rat (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Varenicline may have minor or moderate influence on the ability to drive and use machines. Varenicline may cause dizziness, somnolence and transient loss of consciousness, and therefore may influence the ability to drive and use machines. Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medicinal product affects their ability to perform these activities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Summary of the safety profile</u></p><p dir="ltr">Smoking cessation with or without treatment is associated with various symptoms. For example, dysphoric or depressed mood; insomnia, irritability, frustration or anger; anxiety; difficulty concentrating; restlessness; decreased heart rate; increased appetite or weight gain have been reported in patients attempting to stop smoking. No attempt has been made in either the design or the analysis of the Varenicline studies to distinguish between adverse reactions associated with study drug treatment or those possibly associated with nicotine withdrawal. Adverse drug reactions are based on evaluation of data from pre-marketing phase 2-3 studies and updated based on pooled data from 18 placebo-controlled pre- and post-marketing studies, including approximately 5,000 patients treated with varenicline.</p><p dir="ltr">In patients treated with the recommended dose of 1 mg twice daily following an initial titration period the adverse event most commonly reported was nausea (28.6%). In the majority of cases nausea occurred early in the treatment period, was mild to moderate in severity and seldom resulted in discontinuation.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Tabulated summary of adverse reactions</u></p><p dir="ltr">In the table below all adverse reactions, which occurred at an incidence greater than placebo are listed by system organ class and frequency (very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100) and rare (&ge; 1/10,000 to &lt; 1/1,000)). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p dir="ltr">- Very common: may affect more than 1 in 10 people<br />&bull; Inflammation of the nose and throat, abnormal dreams, difficulty sleeping, headache,<br />&bull; Nausea</p><p dir="ltr">- Common: may affect up to 1 in 10 people<br />&bull; Chest infection, inflammation of the sinuses<br />&bull; Increased weight, decreased appetite, increased appetite<br />&bull; Sleepiness, dizziness, changes in the way things taste<br />&bull; Shortness of breath, cough<br />&bull; Heartburn, vomiting, constipation, diarrhoea, feeling bloated, abdominal pain, toothache, indigestion, flatulence, dry mouth<br />&bull; Skin rash, itching<br />&bull; Joint ache, muscle ache, back pain<br />&bull; Chest pain, tiredness</p><p dir="ltr">Uncommon: may affect up to 1 in 100 people<br />&bull; Fungal infection, viral infection<br />&bull; Feeling of panic, difficulty thinking, restlessness, mood swings, depression, anxiety, hallucinations, changes in sex drive<br />&bull; Seizure, tremor, feeling sluggish, less sensitive to touch<br />&bull; Conjunctivitis, eye pain<br />&bull; Ringing in the ears<br />&bull; Angina, rapid heart rate, palpitations, increased heart rate<br />&bull; Increased blood pressure, hot flush<br />&bull; Inflammation of nose, sinuses and throat, congestion of nose, throat and chest, hoarseness, hay fever, throat irritation, congested sinuses, excess mucous from nose causing cough, runny nose<br />&bull; Red blood in stools, irritated stomach, change of bowel habit, belching, mouth ulcers, pain in the gums<br />&bull; Reddening of the skin, acne, increased sweating, night sweats<br />&bull; Muscle spasms, chest wall pain<br />&bull; Abnormally frequent urination, urination at night<br />&bull; Increased menstrual flow<br />&bull; Chest discomfort, flu like illness, fever, feeling weak or unwell<br />&bull; High blood sugar<br />&bull; Heart attack<br />&bull; Suicidal thoughts<br />&bull; Changes in thinking or behaviour (such as aggression)</p><p dir="ltr">Rare: may affect up to 1 in 1,000 people<br />&bull; Excessive thirst<br />&bull; Feeling unwell or unhappy, slow thinking<br />&bull; Stroke<br />&bull; Increased muscle tension, difficulty with speech, difficulty with coordination, reduced sense of taste, altered sleep pattern<br />&bull; Disturbed vision, eyeball discolouration, dilated pupils, sensitivity to light, shortsightedness, watery eyes<br />&bull; Irregular heart beat or heart rhythm disturbances<br />&bull; Throat pain, snoring<br />&bull; Blood in vomit, abnormal stools, coated tongue<br />&bull; Stiff joints, rib pain<br />&bull; Glucose in urine, increased urine volume and frequency<br />&bull; Vaginal discharge, changes in sexual ability<br />&bull; Feeling cold, cyst<br />&bull; Diabetes<br />&bull; Sleep walking<br />&bull; Loss of contact with reality and unable to think or judge clearly (psychosis)<br />&bull; Abnormal behaviour<br />&bull; Severe skin reactions including Erythema Multiforme (a type of rash) and Stevens-Johnson Syndrome (a serious illness with blistering of the skin, mouth, around the eyes or genitals)<br />&bull; Serious allergic reactions including angioedema (swelling of the face, mouth, or throat)</p><p dir="ltr">- Not known<br />&bull; Transient loss of consciousness</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No cases of overdose were reported in pre-marketing clinical trials.</p><p dir="ltr">In case of overdose, standard supportive measures should be instituted as required.</p><p dir="ltr">Varenicline has been shown to be dialyzed in patients with end stage renal disease (see section 5.2), however, there is no experience in dialysis following overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Other nervous system drugs; Drugs used in addictive disorders; Drugs used in nicotine dependence, ATC code: N07BA03</p><p dir="ltr"><u>Mechanism of action</u></p><p dir="ltr">Varenicline binds with high affinity and selectivity at the &alpha;4&beta;2 neuronal nicotinic acetylcholine receptors, where it acts as a partial agonist - a compound that has both agonist activity, with lower intrinsic efficacy than nicotine, and antagonist activities in the presence of nicotine.</p><p dir="ltr">Electrophysiology studies <em>in vitro</em> and neurochemical studies in vivo have shown that varenicline binds to the &alpha;4&beta;2 neuronal nicotinic acetylcholine receptors and stimulates receptor-mediated activity, but at a significantly lower level than nicotine. Nicotine competes for the same human &alpha;4&beta;2 nAChR binding site for which varenicline has higher affinity.</p><p dir="ltr">Therefore, varenicline can effectively block nicotine&#39;s ability to fully activate &alpha;4&beta;2 receptors and the mesolimbic dopamine system, the neuronal mechanism underlying reinforcement and reward experienced upon smoking. Varenicline is highly selective and binds more potently to the &alpha;4&beta;2 receptor subtype (Ki=0.15 nM) than to other common nicotinic receptors (&alpha;3&beta;4 Ki=84 nM, &alpha;7 Ki= 620 nM, &alpha;1&beta;&gamma;&delta; Ki= 3,400 nM), or to non-nicotinic receptors and transporters (Ki &gt; 1&micro;M, except to 5-HT3 receptors: Ki=350 nM).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pharmacodynamic effects</u></p><p dir="ltr">The efficacy of Varenicline in smoking cessation is a result of varenicline&#39;s partial agonist activity at the &alpha;4&beta;2 nicotinic receptor where its binding produces an effect sufficient to alleviate symptoms of craving and withdrawal (agonist activity), while simultaneously resulting in a reduction of the rewarding and reinforcing effects of smoking by preventing nicotine binding to &alpha;4&beta;2 receptors (antagonist activity).</p><p dir="ltr"><u>Clinical efficacy and safety</u></p><p dir="ltr">Smoking cessation therapies are more likely to succeed for patients who are motivated to stop smoking and who are provided with additional advice and support.</p><p dir="ltr">The efficacy of Varenicline in smoking cessation was demonstrated in 3 clinical trials involving chronic cigarette smokers (&ge; 10 cigarettes per day). Two thousand six hundred nineteen (2619) patients received Varenicline 1 mg BID (titrated during the first week), 669 patients received bupropion 150 mg BID (also titrated) and 684 patients received placebo.</p><p dir="ltr"><em>Comparative clinical studies</em></p><p dir="ltr">Two identical double-blind clinical trials prospectively compared the efficacy of Varenicline (1 mg twice daily), sustained release bupropion (150 mg twice daily) and placebo in smoking cessation. In these 52-week duration studies, patients received treatment for 12 weeks, followed by a 40-week non-treatment phase.</p><p dir="ltr">The primary endpoint of the two studies was the carbon monoxide (CO) confirmed, 4-week continuous quit rate (4W- CQR) from week 9 through week 12. The primary endpoint for Varenicline demonstrated statistical superiority to bupropion and placebo.</p><p dir="ltr">After the 40 week non-treatment phase, a key secondary endpoint for both studies was the Continuous Abstinence Rate (CA) at week 52. CA was defined as the proportion of all subjects treated who did not smoke (not even a puff of a cigarette) from Week 9 through Week 52 and did not have an exhaled CO measurement of &gt; 10 ppm.</p><p dir="ltr">The 4W-CQR (weeks 9 through 12) and CA rate (weeks 9 through 52) from studies 1 and 2 are included in the following table:</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:994px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Study 1 (n=1022)</p></td><td colspan="2" style="vertical-align:top; width:550px"><p>Study 2 (n=1023)</p></td></tr><tr><td style="vertical-align:top"><p>4W CQR</p></td><td style="vertical-align:top"><p>CA Wk 9-52</p></td><td style="vertical-align:top"><p>4W CQR</p></td><td style="vertical-align:top; width:443px"><p>CA Wk 9-52</p></td></tr><tr><td style="vertical-align:top"><p>Varenicline</p></td><td style="vertical-align:top"><p>44.4%</p></td><td style="vertical-align:top"><p>22.1%</p></td><td style="vertical-align:top"><p>44.0%</p></td><td style="vertical-align:top; width:443px"><p>23.0%</p></td></tr><tr><td style="vertical-align:top"><p>Bupropion</p></td><td style="vertical-align:top"><p>29.5%</p></td><td style="vertical-align:top"><p>16.4%</p></td><td style="vertical-align:top"><p>30.0%</p></td><td style="vertical-align:top; width:443px"><p>15.0%</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>17.7%</p></td><td style="vertical-align:top"><p>8.4%</p></td><td style="vertical-align:top"><p>17.7%</p></td><td style="vertical-align:top; width:443px"><p>10.3%</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio</p><p>Varenicline vs. placebo</p></td><td style="vertical-align:top"><p>3.91</p><p>p &lt; 0.0001</p></td><td style="vertical-align:top"><p>3.13</p><p>p &lt; 0.0001</p></td><td style="vertical-align:top"><p>3.85</p><p>p &lt; 0.0001</p></td><td style="vertical-align:top; width:443px"><p>2.66</p><p>p &lt; 0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio</p><p>Varenicline vs. bupropion</p></td><td style="vertical-align:top"><p>1.96</p><p>p &lt; 0.0001</p></td><td style="vertical-align:top"><p>1.45</p><p>p = 0.0640</p></td><td style="vertical-align:top"><p>1.89</p><p>p &lt; 0.0001</p></td><td style="vertical-align:top; width:443px"><p>1.72</p><p>p = 0.0062</p><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Patient reported craving, withdrawal and reinforcing effects of smoking</u></p><p dir="ltr">Across both Studies 1 and 2 during active treatment, craving and withdrawal were significantly reduced in patients randomised to Varenicline in comparison with placebo. Varenicline also significantly reduced reinforcing effects of smoking that can perpetuate smoking behaviour in patients who smoke during treatment compared with placebo. The effect of varenicline on craving, withdrawal and reinforcing effects of smoking were not measured during the non-treatment long- term follow-up phase.</p><p dir="ltr"><u>Maintenance of abstinence study</u></p><p dir="ltr">The third study assessed the benefit of an additional 12 weeks of Varenicline therapy on the maintenance of abstinence. Patients in this study (n=1,927) received open-label Varenicline 1 mg twice daily for 12 weeks. Patients who stopped smoking by Week 12 were then randomised to receive either Varenicline (1 mg twice daily) or placebo for an additional 12 weeks for a total study duration of 52 weeks.</p><p dir="ltr">The primary study endpoint was the CO-confirmed continuous abstinence rate from week 13 through week 24 in the double-blind treatment phase. A key secondary endpoint was the continuous abstinence (CA) rate for week 13 through week 52.</p><p dir="ltr">This study showed the benefit of an additional 12-week treatment with Varenicline 1 mg twice daily for the maintenance of smoking cessation compared to placebo; superiority to</p><p dir="ltr">&nbsp; placebo for CA was maintained through week 52. The key results are summarised in the following table:</p><p>&nbsp;</p><p>Continuous Abstinence Rates in Subjects Treated with Varenicline versus Placebo</p><table border="1" cellspacing="0" cellpadding="0" style="width:1001px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Varenicline n=602</p></td><td style="vertical-align:top"><p>Placebo</p><p>n=604</p></td><td style="vertical-align:top"><p>Difference</p><p>(95% CI)</p></td><td style="vertical-align:top; width:492px"><p>Odds ratio</p><p>(95% CI)</p></td></tr><tr><td><p>CA* wk 13-24</p></td><td><p>70.6%</p></td><td><p>49.8%</p></td><td><p>20.8%</p><p>(15.4%, 26.2%)</p></td><td style="width:492px"><p>2.47</p><p>(1.95, 3.15)</p></td></tr><tr><td><p>&nbsp;</p><p>CA* wk 13-52</p></td><td><p>44.0%</p></td><td><p>37.1%</p></td><td><p>6.9%</p><p>(1.4%, 12.5%)</p></td><td style="width:492px"><p>1.35</p><p>(1.07, 1.70)</p></td></tr></tbody></table><p dir="ltr">*CA: Continuous Abstinence Rate</p><p dir="ltr">There is currently limited clinical experience with the use of Varenicline among black people to determine clinical efficacy.</p><p dir="ltr"><em>Flexible quit date between weeks 1 and 5</em></p><p dir="ltr">The efficacy and safety of varenicline has been evaluated in smokers who had the flexibility of quitting between weeks 1 and 5 of treatment. In this 24-week study, patients received treatment for 12 weeks followed by a 12 week non-treatment follow up phase. The 4 week (week 9-12) CQR for varenicline and placebo was 53.9% and 19.4%, respectively (difference=34.5%, 95% CI: 27.0% - 42.0%) and the CA week 9-24 was 35.2% (varenicline) vs. 12.7% (placebo) (difference=22.5%, 95% CI: 15.8% - 29.1%). Patients who are not willing or able to set the target quit date within 1-2 weeks, could be offered to start treatment and then choose their own quit date within 5 weeks.</p><p dir="ltr"><em>Study in subjects re-treated with Varenicline</em></p><p dir="ltr">Varenicline was evaluated in a double-blind, placebo-controlled trial of 494 patients who had made a previous attempt to quit smoking with varenicline, and either did not succeed in quitting or relapsed after treatment. Subjects who experienced an adverse event of a concern during previous treatment were excluded. Subjects were randomised 1:1 to varenicline 1 mg twice daily (N=249) or placebo (N=245) for 12 weeks of treatment and followed for up to 40 weeks post- treatment. Patients included in this study had taken varenicline for a smoking-cessation attempt in the past (for a total treatment duration of a minimum of two weeks), at least three months prior to study entry, and had been smoking for at least four weeks.</p><p dir="ltr">Patients treated with varenicline had a superior rate of CO-confirmed abstinence during weeks 9 through 12 and from weeks 9 through 52 compared to subjects treated with placebo. The key results are summarised in the following table:</p><p><strong>Continuous Abstinence Rates in Subjects Treated with varenicline versus Placebo</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:1017px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>varenicline</p><p>n=249</p></td><td style="vertical-align:top"><p>Placebo</p><p>n=245</p></td><td style="vertical-align:top; width:623px"><p>Odds ratio (95% CI),</p><p>p value</p></td></tr><tr><td style="vertical-align:top"><p>CA* wk 9-12</p></td><td style="vertical-align:top"><p>45.0%</p></td><td style="vertical-align:top"><p>11.8%</p></td><td style="vertical-align:top; width:623px"><p>7.08 (4.34, 11.55),</p><p>p&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>CA* wk 9-52</p></td><td style="vertical-align:top"><p>20.1%</p></td><td style="vertical-align:top"><p>3.3%</p></td><td style="vertical-align:top; width:623px"><p>9.00 (3.97, 20.41),</p><p>p&lt;0.0001</p></td></tr></tbody></table><p>*CA: Continuous Abstinence Rate</p><p><em>Gradual approach to quitting smoking</em></p><p>Varenicline was evaluated in a 52-week double-blind placebo-controlled study of 1,510 subjects who were not able or willing to quit smoking within four weeks but were willing to gradually reduce their smoking over a 12 week period before quitting. Subjects were randomised to either varenicline 1 mg twice daily (n=760) or placebo (n=750) for 24 weeks and followed up post-treatment through week 52. Subjects were instructed to reduce the number of cigarettes smoked by at least 50 percent by the end of the first four weeks of treatment, followed by a further 50 percent reduction from week four to week eight of treatment, with the goal of reaching complete abstinence by 12 weeks. After the initial 12-week reduction phase, subjects continued treatment for another 12 weeks. Subjects treated with varenicline had a significantly higher Continuous Abstinence Rate compared with placebo; the key results are summarised in the following table:</p><p><strong>Continuous Abstinence Rates in Subjects Treated with Varenicline versus Placebo</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:1018px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Varenicline</p><p>n=760</p></td><td style="vertical-align:top"><p>Placebo</p><p>n=750</p></td><td style="vertical-align:top; width:608px"><p>Odds ratio (95% CI),</p><p>p value</p></td></tr><tr><td style="vertical-align:top"><p>CA* wk 15-24</p></td><td><p>32.1%</p></td><td><p>6.9%</p></td><td style="width:608px"><p>8.74 (6.09, 12.53),</p><p>p&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>CA* wk 21-52</p></td><td><p>27.0%</p></td><td><p>9.9%</p></td><td style="width:608px"><p>4.02 (2.94, 5.50),</p><p>p&lt;0.0001</p></td></tr><tr><td colspan="4" style="width:1015px"><p>*CA: Continuous Abstinence Rate</p></td></tr></tbody></table><p dir="ltr">The Varenicline safety profile in this study was consistent with that of pre-marketing studies.</p><p dir="ltr"><em>Subjects with cardiovascular disease</em></p><p dir="ltr">Varenicline was evaluated in a randomised, double-blind, placebo-controlled study of subjects with stable, cardiovascular disease (other than, or in addition to, hypertension) that had been diagnosed for more than 2 months. Subjects were randomised to Varenicline 1 mg twice daily (n=353) or placebo (n=350) for 12 weeks and then were followed for 40 weeks post-treatment. The 4 week CQR for varenicline and placebo was 47.3% and 14.3%, respectively and the CA week 9-52 was 19.8% (varenicline) vs. 7.4% (placebo).</p><p dir="ltr">Deaths and serious cardiovascular events were adjudicated by a blinded, committee. The following adjudicated events occurred with a frequency &ge; 1% in either treatment group during treatment (or in the 30-day period after treatment): nonfatal myocardial infarction (1.1% vs. 0.3% for Varenicline and placebo, respectively), and hospitalization for angina pectoris (0.6% vs. 1.1%). During non-treatment follow up to 52 weeks, the adjudicated events included need for coronary revascularisation (2.0% vs. 0.6%), hospitalisation for angina pectoris (1.7% vs. 1.1%), and new diagnosis of peripheral vascular disease (PVD) or admission for a PVD procedure (1.4% vs. 0.6%). Some of the patients requiring coronary revascularisation underwent the procedure as part of management of nonfatal MI and hospitalisation for angina.</p><p dir="ltr">Cardiovascular death occurred in 0.3% of patients in the Varenicline arm and 0.6% of patients in the placebo arm over the course of the 52-week study.</p><p dir="ltr">A meta-analysis of 15 clinical trials of &ge; 12 weeks treatment duration, including 7002 patients (4190 Varenicline, 2812 placebo), was conducted to systematically assess the cardiovascular safety of Varenicline. The study in patients with stable cardiovascular disease described above was included in the meta-analysis.</p><p dir="ltr">The key cardiovascular safety analysis included occurrence and timing of a composite endpoint of Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, nonfatal MI, and nonfatal stroke. These events included in the endpoint were adjudicated by a blinded, independent committee. Overall, a small number of MACE occurred during treatment in the trials included in the meta-analysis (Varenicline 7 [0.17%]; placebo 2 [0.07%]).</p><p dir="ltr">Additionally, a small number of MACE occurred up to 30 days after treatment (Varenicline 13 [0.31%]; placebo 6 [0.21%]).</p><p dir="ltr">The meta-analysis showed that exposure to Varenicline resulted in a hazard ratio for MACE of 2.83 (95% confidence interval from 0.76 to 10.55, p=0.12) for patients during treatment and 1.95 (95% confidence interval from 0.79 to 4.82, p=0.15) for patients up to 30 days after treatment. These are equivalent to an estimated increase of 6.5 MACE events and 6.3 MACE events per 1,000 patient-years, respectively of exposure. The hazard ratio for MACE was higher in patients with cardiovascular risk factors in addition to smoking compared with that in patients without cardiovascular risk factors other than smoking. There were similar rates of all-cause mortality (Varenicline 6 [0.14%]; placebo 7 [0.25%]) and cardiovascular mortality (Varenicline 2 [0.05%]; placebo 2 [0.07%]) in the Varenicline arms compared with the placebo arms in the meta-analysis.</p><p dir="ltr"><em>Cardiovascular safety assessment study in subjects with and without a history of psychiatric disorder</em></p><p dir="ltr">The cardiovascular (CV) safety of Varenicline &nbsp;was evaluated in the Study in Subjects with and without a History of Psychiatric Disorder (parent study; see section 5.1 - <em>Neuropsychiatric safety</em>) and its non-treatment extension, the Cardiovascular Safety Assessment Study, which enrolled 4595 of the 6293 subjects who completed the parent study (N=8058) and followed them through week 52. Of all subjects treated in the parent study, 1749 (21.7%) had a medium CV risk and 644 (8.0%) had a high CV risk, as defined by Framingham score.</p><p dir="ltr">The primary CV endpoint was the time to major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal myocardial infarction or non-fatal stroke during treatment. Deaths and cardiovascular events were adjudicated by a blinded, independent committee.</p><p dir="ltr">The following table shows the incidence of MACE and Hazard Ratios vs placebo for all treatment groups during treatment, and cumulative for treatment plus 30 days and through end of study.</p><table border="1" cellspacing="0" cellpadding="0" style="width:1023px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Varenicline N=2016</strong></p></td><td style="vertical-align:top"><p><strong>Bupropion</strong></p><p><strong>N=2006</strong></p></td><td style="vertical-align:top"><p><strong>NRT</strong></p><p><strong>N=2022</strong></p></td><td style="vertical-align:top; width:462px"><p><strong>Placebo</strong></p><p><strong>N=2014</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top; width:1020px"><p><strong><em>During treatment</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>MACE, n (%)</p></td><td style="vertical-align:top"><p>1 (0.05)</p></td><td style="vertical-align:top"><p>2 (0.10)</p></td><td style="vertical-align:top"><p>1 (0.05)</p></td><td style="vertical-align:top; width:462px"><p>4 (0.20)</p></td></tr><tr><td style="vertical-align:top"><p><em>Hazard Ratio (95% CI) vs placebo</em></p></td><td style="vertical-align:top"><p>0.29 (0.05, 1.68)</p></td><td style="vertical-align:top"><p>0.50 (0.10, 2.50)</p></td><td style="vertical-align:top"><p>0.29 (0.05, 1.70)</p></td><td style="vertical-align:top; width:462px"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top; width:1020px"><p><strong><em>During treatment plus 30 days</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>MACE, n (%)</p></td><td style="vertical-align:top"><p>1 (0.05)</p></td><td style="vertical-align:top"><p>2 (0.10)</p></td><td style="vertical-align:top"><p>2 (0.10)</p></td><td style="vertical-align:top; width:462px"><p>4 (0.20)</p></td></tr><tr><td style="vertical-align:top"><p><em>Hazard Ratio (95% CI) vs placebo</em></p></td><td><p>0.29 (0.05, 1.70)</p></td><td><p>0.51 (0.10, 2.51)</p></td><td><p>0.50 (0.10, 2.48)</p></td><td style="vertical-align:top; width:462px"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="width:1020px"><p><strong><em>Through end of study</em></strong></p></td></tr><tr><td><p>MACE, n (%)</p></td><td><p>3 (0.15)</p></td><td><p>9 (0.45)</p></td><td><p>6 (0.30)</p></td><td style="width:462px"><p>8 (0.40)</p></td></tr><tr><td><p><em>Hazard Ratio (95% CI) vs placebo</em></p></td><td><p>0.39 (0.12, 1.27)</p></td><td><p>1.09 (0.42, 2.83)</p></td><td><p>0.75 (0.26, 2.13)</p></td><td style="width:462px"><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">The use of Varenicline, bupropion, and NRT was not associated with an increased risk of CV AEs in smokers treated for up to 12 weeks and followed for up to 1 year compared to placebo, although because of the relatively low number of events overall, an association cannot be entirely ruled out.</p><p dir="ltr"><em>Subjects with mild-moderate chronic obstructive pulmonary disease (COPD)</em></p><p dir="ltr">The efficacy and safety of Varenicline (1 mg twice daily) for smoking cessation in subjects with mild-moderate COPD was demonstrated in a randomised double-blind placebo-controlled clinical trial. In this 52-week duration study, patients received treatment for 12 weeks, followed by a 40-week non-treatment follow-up phase. The primary endpoint of the study was the CO-confirmed, 4-week Continuous Quit Rate (4W CQR) from week 9 through week 12 and a key secondary endpoint was the Continuous Abstinence (CA) from Week 9 through Week 52. The safety profile of varenicline was comparable to what was reported in other trials in the general population, including pulmonary safety.</p><p dir="ltr">The results for the 4W CQR (weeks 9 through 12) and CA rate (weeks 9 through 52) are shown in the following table:</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:1021px"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>4W CQR</strong></p></td><td style="width:566px"><p><strong>CA Wk 9-52</strong></p></td></tr><tr><td><p>Varenicline, (n = 248)</p></td><td><p>42.3%</p></td><td style="width:566px"><p>18.5%</p></td></tr><tr><td><p>Placebo, (n = 251)</p></td><td><p>8.8%</p></td><td style="width:566px"><p>5.6%</p></td></tr><tr><td><p>Odds ratio</p><p>(Varenicline vs. Placebo)</p></td><td><p>8.40</p><p>p &lt; 0.0001</p></td><td style="width:566px"><p>4.04</p><p>p &lt; 0.0001</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Study in subjects with a history of major depressive disorder</em></p><p dir="ltr">The efficacy of varenicline was confirmed in a randomised placebo-controlled trial in 525 subjects with a history of major depression in the past two years or under current stable treatment. The cessation rates in this population were similar to those reported in the general population. Continuous abstinence rate between weeks 9-12 was 35.9% in the varenicline treatment group versus 15.6% in the placebo group (OR 3.35 (95% CI 2.16-5.21)) and between weeks 9-52 was 20.3% versus 10.4% respectively (OR 2.36 (95% CI 1.40-3.98)). The most common adverse events (&ge; 10%) in subjects taking varenicline were nausea (27.0% vs. 10.4% on placebo), headache (16.8% vs. 11.2%), abnormal dreams (11.3% vs. 8.2%), insomnia (10.9% vs. 4.8%) and irritability (10.9% vs. 8.2%). Psychiatric scales showed no differences between the varenicline and placebo groups and no overall worsening of depression, or other psychiatric symptoms, during the study in either treatment group.</p><p dir="ltr"><em>Study in subjects with stable schizophrenia or schizoaffective disorder</em></p><p dir="ltr">Varenicline safety and tolerability was assessed in a double-blind study of 128 smokers with stable schizophrenia or schizoaffective disorder, on antipsychotic medication, randomised 2:1 to varenicline (1 mg twice daily) or placebo for 12 weeks with 12-week non-drug follow-up.</p><p dir="ltr">The most common adverse events in subjects taking varenicline were nausea (23.8% vs. 14.0% on placebo), headache (10.7% vs. 18.6% on placebo) and vomiting (10.7% vs. 9.3% on placebo). Among reported neuropsychiatric adverse events, insomnia was the only event reported in either treatment group in &ge; 5% of subjects at a rate higher in the varenicline group than in placebo (9.5% vs. 4.7%).</p><p dir="ltr">Overall, there was no worsening of schizophrenia in either treatment group as measured by psychiatric scales and there were no overall changes in extra-pyramidal signs. In the varenicline group compared to placebo, a higher proportion of subjects reported suicidal ideation or behaviour prior to enrolment (lifetime history) and after the end of active treatment period (on Days 33 to 85 after the last dose of treatment). During the active treatment period, the incidence of suicide- related events was similar between the varenicline-treated and the placebo-treated subjects (11 vs. 9.3%, respectively). The percentage of subjects with suicide-related events in the active treatment phase compared to post-treatment phase was unchanged in the varenicline group; in the placebo group, this percentage was lower in the post-treatment phase. Although there were no completed suicides, there was one suicidal attempt in a varenicline-treated subject whose lifetime history included several similar attempts. The limited data available from this single smoking cessation study are not sufficient to allow for definitive conclusions to be drawn about the safety in patients with schizophrenia or schizoaffective disorder.</p><p dir="ltr"><em>Neuropsychiatric Safety Study in Subjects with and without a History of Psychiatric Disorder: </em>Varenicline was evaluated in a randomised, double-blind, active and placebo-controlled study that included subjects with a history of psychiatric disorder (psychiatric cohort, N=4074) and subjects without a history of psychiatric disorder (non-psychiatric cohort, N=3984). Subjects aged 18-75 years, smoking 10 or more cigarettes per day were randomised 1:1:1:1 to varenicline 1 mg BID, bupropion SR 150 mg BID, nicotine replacement therapy patch (NRT) 21 mg/day with taper or placebo for a treatment period of 12 weeks; they were then followed for another 12 weeks post-treatment.</p><p dir="ltr">The primary safety endpoint was a composite of the following neuropsychiatric (NPS) adverse events: severe events of anxiety, depression, feeling abnormal, or hostility, and/or moderate or severe events of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behaviour or completed suicide.</p><p dir="ltr">The following table shows the rates of the composite NPS adverse event primary endpoint by treatment group and the risk differences (RDs) (95% CI) vs placebo in the <strong>non-psychiatric cohort</strong>.</p><p dir="ltr">In addition, the table shows the subset of the composite NPS AE endpoint of severe intensity:</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:1016px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top; width:713px"><p><strong>Non-psychiatric Cohort</strong></p><p><strong>N=3984</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Varenicline</strong></p></td><td style="vertical-align:top"><p><strong>Bupropion</strong></p></td><td style="vertical-align:top"><p><strong>NRT</strong></p></td><td style="vertical-align:top; width:465px"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of Patients Treated</strong></p></td><td style="vertical-align:top"><p>990</p></td><td style="vertical-align:top"><p>989</p></td><td style="vertical-align:top"><p>1006</p></td><td style="vertical-align:top; width:465px"><p>999</p></td></tr><tr><td style="vertical-align:top"><p><strong>Composite NPS AE Primary Endpoint, n (%)</strong></p></td><td style="vertical-align:top"><p>13 (1.3)</p></td><td style="vertical-align:top"><p>22 (2.2)</p></td><td style="vertical-align:top"><p>25 (2.5)</p></td><td style="vertical-align:top; width:465px"><p>24 (2.4)</p></td></tr><tr><td><p><strong>RD (95% CI) vs Placebo</strong></p></td><td style="vertical-align:top"><p>-1.28</p><p>(-2.40, -0.15)</p></td><td style="vertical-align:top"><p>-0.08</p><p>(-1.37, 1.21)</p></td><td style="vertical-align:top"><p>-0.21</p><p>(-1.54,1.12)</p></td><td style="vertical-align:top; width:465px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Composite NPS AE Endpoint of severe intensity n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1 (0.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4 (0.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>3 (0.3)</p></td><td style="vertical-align:top; width:465px"><p>&nbsp;</p><p>5 (0.5)</p></td></tr></tbody></table><p dir="ltr">AE, adverse event; NRT=Nicotine replacement therapy patch</p><p dir="ltr">The rates of events in the composite endpoint were low across all treatment groups and were similar or lower for each of the active treatments compared to placebo. The use of varenicline, bupropion and NRT in the non-psychiatric cohort was not associated with a significantly increased risk of NPS adverse events in the composite primary endpoint compared with placebo (95% CIs were lower than or included zero).</p><p dir="ltr">The percentage of subjects with suicidal ideation and/or behaviour based on the Columbia-Suicide Severity Rating Scale (C-SSRS) was similar between the varenicline and placebo groups during treatment and in the non- treatment follow-up, as shown in the following table:</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:1014px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top; width:786px"><p><strong>Non-psychiatric Cohort N=3984</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Varenicline</strong></p><p><strong>N=990 n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Bupropion</strong></p><p><strong>N=989 n (%)</strong></p></td><td style="vertical-align:top"><p><strong>NRT</strong></p><p><strong>N=1006 n (%)</strong></p></td><td style="vertical-align:top; width:496px"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Placebo</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; N=999 n (%)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top; width:1011px"><p><strong>During treatment</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number assessed</p></td><td style="vertical-align:top"><p>988</p></td><td style="vertical-align:top"><p>983</p></td><td style="vertical-align:top"><p>996</p></td><td style="vertical-align:top; width:496px"><p>995</p></td></tr><tr><td style="vertical-align:top"><p>Suicidal behaviour and/or ideation</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7 (0.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4 (0.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>3 (0.3)</p></td><td style="vertical-align:top; width:496px"><p>&nbsp;</p><p>7 (0.7)</p></td></tr><tr><td style="vertical-align:top"><p>Suicidal behaviour</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1 (0.1)</p></td><td style="vertical-align:top; width:496px"><p>1 (0.1)</p></td></tr><tr><td style="vertical-align:top"><p>Suicidal ideation</p></td><td style="vertical-align:top"><p>7 (0.7)</p></td><td style="vertical-align:top"><p>4 (0.4)</p></td><td style="vertical-align:top"><p>3 (0.3)</p></td><td style="vertical-align:top; width:496px"><p>6 (0.6)</p></td></tr><tr><td colspan="5" style="vertical-align:top; width:1011px"><p><strong>During follow up</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number assessed</p></td><td style="vertical-align:top"><p>807</p></td><td style="vertical-align:top"><p>816</p></td><td style="vertical-align:top"><p>800</p></td><td style="vertical-align:top; width:496px"><p>805</p></td></tr><tr><td style="vertical-align:top"><p>Suicidal behaviour and/or ideation</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>3 (0.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2 (0.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>3 (0.4)</p></td><td style="vertical-align:top; width:496px"><p>&nbsp;</p><p>4 (0.5)</p></td></tr><tr><td style="vertical-align:top"><p>Suicidal behaviour</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1 (0.1)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top; width:496px"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Suicidal ideation</p></td><td style="vertical-align:top"><p>3 (0.4)</p></td><td style="vertical-align:top"><p>2 (0.2)</p></td><td style="vertical-align:top"><p>3 (0.4)</p></td><td style="vertical-align:top; width:496px"><p>4 (0.5)</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">NRT=Nicotine replacement therapy patch</p><p dir="ltr">There was one completed suicide, which occurred during treatment in a subject treated with placebo in the non- psychiatric cohort.</p><p dir="ltr">The following table shows the rates of the composite NPS adverse event primary endpoint by treatment group and the RDs (95% CI) vs placebo in the psychiatric cohort. The individual components of the endpoint are also shown.</p><p dir="ltr">In addition, the table shows the subset of the composite NPS AE endpoint of severe intensity:</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:1015px"><tbody><tr><td rowspan="2"><p>&nbsp;</p></td><td colspan="4" style="width:709px"><p><strong>Psychiatric Cohort N=4074</strong></p></td></tr><tr><td><p><strong>Varenicline</strong></p></td><td><p><strong>Bupropion</strong></p></td><td><p><strong>NRT</strong></p></td><td style="width:453px"><p><strong>Placebo</strong></p></td></tr><tr><td><p><strong>Number of Patients Treated</strong></p></td><td><p>1026</p></td><td><p>1017</p></td><td><p>1016</p></td><td style="width:453px"><p>1015</p></td></tr><tr><td><p><strong>Composite NPS AE Primary Endpoint, n (%)</strong></p></td><td><p>67 (6.5)</p></td><td><p>68 (6.7)</p></td><td><p>53 (5.2)</p></td><td style="width:453px"><p>50 (4.9)</p></td></tr><tr><td><p><strong>RD (95% CI) vs Placebo</strong></p></td><td><p>1.59</p><p>(-0.42, 3.59)</p></td><td><p>1.78</p><p>(-0.24, 3.81)</p></td><td><p>0.37</p><p>(-1.53, 2.26)</p></td><td style="width:453px"><p>&nbsp;</p></td></tr><tr><td><p><strong>NPS AE Primary Endpoint Components n (%):</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td style="width:453px"><p>&nbsp;</p></td></tr><tr><td><p>Anxietya</p></td><td><p>5 (0.5)</p></td><td><p>4 (0.4)</p></td><td><p>6 (0.6)</p></td><td style="width:453px"><p>2 (0.2)</p></td></tr><tr><td><p>Depressiona</p></td><td><p>6 (0.6)</p></td><td><p>4 (0.4)</p></td><td><p>7 (0.7)</p></td><td style="width:453px"><p>6 (0.6)</p></td></tr><tr><td><p>Feeling abnormala</p></td><td><p>0</p></td><td><p>1 (0.1)</p></td><td><p>0</p></td><td style="width:453px"><p>0</p></td></tr><tr><td><p>Hostilitya</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td style="width:453px"><p>0</p></td></tr><tr><td><p>Agitationb</p></td><td><p>25 (2.4)</p></td><td><p>29 (2.9)</p></td><td><p>21 (2.1)</p></td><td style="width:453px"><p>22 (2.2)</p></td></tr><tr><td><p>Aggressionb</p></td><td><p>14 (1.4)</p></td><td><p>9 (0.9)</p></td><td><p>7 (0.7)</p></td><td style="width:453px"><p>8 (0.8)</p></td></tr><tr><td><p>Delusionsb</p></td><td><p>1 (0.1)</p></td><td><p>1 (0.1)</p></td><td><p>1 (0.1)</p></td><td style="width:453px"><p>0</p></td></tr><tr><td><p>Hallucinationsb</p></td><td><p>5 (0.5)</p></td><td><p>4 (0.4)</p></td><td><p>2 (0.2)</p></td><td style="width:453px"><p>2 (0.2)</p></td></tr><tr><td><p>Homicidal ideationb</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td style="width:453px"><p>0</p></td></tr><tr><td><p>Maniab</p></td><td><p>7 (0.7)</p></td><td><p>9 (0.9)</p></td><td><p>3 (0.3)</p></td><td style="width:453px"><p>6 (0.6)</p></td></tr><tr><td><p>Panicb</p></td><td><p>7 (0.7)</p></td><td><p>16 (1.6)</p></td><td><p>13 (1.3)</p></td><td style="width:453px"><p>7 (0.7)</p></td></tr><tr><td><p>Paranoiab</p></td><td><p>1 (0.1)</p></td><td><p>0</p></td><td><p>0</p></td><td style="width:453px"><p>2 (0.2)</p></td></tr><tr><td><p>Psychosisb</p></td><td><p>4 (0.4)</p></td><td><p>2 (0.2)</p></td><td><p>3 (0.3)</p></td><td style="width:453px"><p>1 (0.1)</p></td></tr><tr><td><p>Suicidal behaviourb</p></td><td><p>1 (0.1)</p></td><td><p>1 (0.1)</p></td><td><p>0</p></td><td style="width:453px"><p>1 (0.1)</p></td></tr><tr><td><p>Suicidal ideationb</p></td><td><p>5 (0.5)</p></td><td><p>2 (0.2)</p></td><td><p>3 (0.3)</p></td><td style="width:453px"><p>2 (0.2)</p></td></tr><tr><td><p>Completed suicideb</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td style="width:453px"><p>0</p></td></tr><tr><td><p><strong>Composite NPS AE Endpoint of severe intensity n (%)</strong></p></td><td><p>&nbsp;</p><p>14 (1.4)</p></td><td><p>&nbsp;</p><p>14 (1.4)</p></td><td><p>&nbsp;</p><p>14 (1.4)</p></td><td style="width:453px"><p>&nbsp;</p><p>13 (1.3)</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">AE, adverse event; <sup>a</sup>Grade = severe intensity AE; <sup>b</sup>Grade = moderate and severe intensity AE; NRT=Nicotine replacement therapy patch</p><p dir="ltr">There were more events reported in patients in the psychiatric cohort in each treatment group compared with the non- psychiatric cohort, and the incidence of events in the composite endpoint was higher for each of the active treatments compared to placebo. However, the use of varenicline, bupropion and NRT in the psychiatric cohort was not associated with a significantly increased risk of NPS adverse events in the composite primary endpoint compared with placebo (95% CIs included zero).</p><p dir="ltr">In the psychiatric cohort, the percentage of subjects with suicidal ideation and/or behaviour based on the Columbia- Suicide Severity Rating Scale (C-SSRS) was similar between the varenicline and placebo groups during treatment and in the non- treatment follow-up, as shown in the following table:</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:1020px"><tbody><tr><td rowspan="2"><p>&nbsp;</p></td><td colspan="4" style="width:778px"><p><strong>Psychiatric Cohort</strong></p><p><strong>N=4074</strong></p></td></tr><tr><td><p><strong>Varenicline</strong></p><p><strong>N=1026 n (%)</strong></p></td><td><p><strong>Bupropion</strong></p><p><strong>N=1017 n (%)</strong></p></td><td><p><strong>NRT</strong></p><p><strong>N=1016 n (%)</strong></p></td><td style="width:466px"><p><strong>Placebo</strong></p><p><strong>N=1015 n (%)</strong></p></td></tr><tr><td colspan="5" style="width:1017px"><p><strong>During treatment</strong></p></td></tr><tr><td><p>Number assessed</p></td><td><p>1017</p></td><td><p>1012</p></td><td><p>1006</p></td><td style="width:466px"><p>1006</p></td></tr><tr><td><p>Suicidal behaviour and/or ideation</p></td><td><p>&nbsp;</p><p>27 (2.7)</p></td><td><p>&nbsp;</p><p>15 (1.5)</p></td><td><p>&nbsp;</p><p>20 (2.0)</p></td><td style="width:466px"><p>&nbsp;</p><p>25 (2.5)</p></td></tr><tr><td><p>Suicidal behaviour</p></td><td><p>0</p></td><td><p>1 (0.1)</p></td><td><p>0</p></td><td style="width:466px"><p>2 (0.2)</p></td></tr><tr><td><p>Suicidal ideation</p></td><td><p>27 (2.7)</p></td><td><p>15 (1.5)</p></td><td><p>20 (2.0)</p></td><td style="width:466px"><p>25 (2.5)</p></td></tr><tr><td colspan="5" style="width:1017px"><p><strong>During follow up</strong></p></td></tr><tr><td><p>Number assessed</p></td><td><p>833</p></td><td><p>836</p></td><td><p>824</p></td><td style="width:466px"><p>791</p></td></tr><tr><td><p>Suicidal behaviour and/or ideation</p></td><td><p>&nbsp;</p><p>14 (1.7)</p></td><td><p>&nbsp;</p><p>4 (0.5)</p></td><td><p>&nbsp;</p><p>9 (1.1)</p></td><td style="width:466px"><p>&nbsp;</p><p>11 (1.4)</p></td></tr><tr><td><p>Suicidal behaviour</p></td><td><p>1 (0.1)</p></td><td><p>0</p></td><td><p>1 (0.1)</p></td><td style="width:466px"><p>1 (0.1)</p></td></tr><tr><td><p>Suicidal ideation</p></td><td><p>14 (1.7)</p></td><td><p>4 (0.5)</p></td><td><p>9 (1.1)</p></td><td style="width:466px"><p>11 (1.4)</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">NRT=Nicotine replacement therapy patch</p><p dir="ltr">There were no completed suicides reported in the psychiatric cohort.</p><p dir="ltr">The most commonly reported adverse events in subjects treated with varenicline in this study were similar to those observed in premarketing studies.</p><p dir="ltr">In both cohorts, subjects treated with varenicline demonstrated statistical superiority of CO-confirmed abstinence during weeks 9 through 12 and 9 through 24 compared to subjects treated with bupropion, nicotine patch and placebo (please see table below).</p><p dir="ltr">The key efficacy results are summarised in the following table:</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:1019px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Non-psychiatric Cohort</strong></p></td><td style="vertical-align:top; width:595px"><p><strong>Psychiatric Cohort</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>CA 9-12 </strong>n/N (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:595px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Varenicline</p></td><td style="vertical-align:top"><p>382/1005 (38.0%)</p></td><td style="vertical-align:top; width:595px"><p>301/1032 (29.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Bupropion</p></td><td style="vertical-align:top"><p>261/1001 (26.1%)</p></td><td style="vertical-align:top; width:595px"><p>199/1033 (19.3%)</p></td></tr><tr><td style="vertical-align:top"><p>NRT</p></td><td style="vertical-align:top"><p>267/1013 (26.4%)</p></td><td style="vertical-align:top; width:595px"><p>209/1025 (20.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>138/1009 (13.7%)</p></td><td style="vertical-align:top; width:595px"><p>117/1026 (11.4%)</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:1016px"><p><strong>Treatment</strong><strong> </strong><strong>Comparisons: </strong>Odds ratio (95% CI), p value</p></td></tr><tr><td style="vertical-align:top"><p>Varenicline vs Placebo</p></td><td style="vertical-align:top"><p>4.00 (3.20, 5.00), P&lt;0.0001</p></td><td style="vertical-align:top; width:595px"><p>3.24 (2.56, 4.11), P&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Bupropion vs Placebo</p></td><td style="vertical-align:top"><p>2.26 (1.80, 2.85), P&lt;0.0001</p></td><td style="vertical-align:top; width:595px"><p>1.87 (1.46, 2.39), P&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>NRT vs Placebo</p></td><td style="vertical-align:top"><p>2.30 (1.83, 2.90), P&lt;0.0001</p></td><td style="vertical-align:top; width:595px"><p>2.00 (1.56, 2.55), P&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Varenicline vs Bupropion</p></td><td style="vertical-align:top"><p>1.77 (1.46, 2.14), P&lt;0.0001</p></td><td style="vertical-align:top; width:595px"><p>1.74 (1.41, 2.14), P&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Varenicline vs NRT</p></td><td style="vertical-align:top"><p>1.74 (1.43, 2.10), P&lt;0.0001</p></td><td style="vertical-align:top; width:595px"><p>1.62 (1.32, 1.99), P&lt;0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:1016px"><p><strong>CA 9-24 </strong>n/N (%)</p></td></tr><tr><td style="vertical-align:top"><p>Varenicline</p></td><td style="vertical-align:top"><p>256/1005 (25.5%)</p></td><td style="vertical-align:top; width:595px"><p>189/1032 (18.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Bupropion</p></td><td style="vertical-align:top"><p>188/1001 (18.8%)</p></td><td style="vertical-align:top; width:595px"><p>142/1033 (13.7%)</p></td></tr><tr><td style="vertical-align:top"><p>NRT</p></td><td style="vertical-align:top"><p>187/1013 (18.5%)</p></td><td style="vertical-align:top; width:595px"><p>133/1025 (13.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>106/1009 (10.5%)</p></td><td style="vertical-align:top; width:595px"><p>85/1026 (8.3%)</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:1016px"><p><strong>Treatment</strong><strong> </strong><strong>Comparisons: </strong>Odds ratio (95% CI), p value</p></td></tr><tr><td style="vertical-align:top"><p>Varenicline vs Placebo</p></td><td style="vertical-align:top"><p>2.99 (2.33, 3.83), P&lt;0.0001</p></td><td style="vertical-align:top; width:595px"><p>2.50 (1.90, 3.29), P&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Bupropion vs Placebo</p></td><td style="vertical-align:top"><p>2.00 (1.54, 2.59), P&lt;0.0001</p></td><td style="vertical-align:top; width:595px"><p>1.77 (1.33, 2.36), P&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>NRT vs Placebo</p></td><td style="vertical-align:top"><p>1.96 (1.51, 2.54), P&lt;0.0001</p></td><td style="vertical-align:top; width:595px"><p>1.65 (1.24, 2.20), P=0.0007</p></td></tr><tr><td style="vertical-align:top"><p>Varenicline vs Bupropion</p></td><td style="vertical-align:top"><p>1.49 (1.20, 1.85), P=0.0003</p></td><td style="vertical-align:top; width:595px"><p>1.41 (1.11, 1.79), P=0.0047</p></td></tr><tr><td style="vertical-align:top"><p>Varenicline vs NRT</p></td><td style="vertical-align:top"><p>1.52 (1.23, 1.89), P=0.0001</p></td><td style="vertical-align:top; width:595px"><p>1.51 (1.19, 1.93), P=0.0008</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">CA = continuous abstinence rate; CI = confidence interval; NRT=Nicotine replacement therapy patch</p><p dir="ltr"><em>Neuropsychiatric Safety Meta-analyses and Observational Studies:</em></p><p dir="ltr">Analyses of clinical trial data did not show evidence of an increased risk of serious neuropsychiatric events with varenicline compared to placebo. In addition, independent observational studies have not supported an increased risk of serious neuropsychiatric events in patients treated with varenicline compared to patients prescribed nicotine replacement therapy (NRT) or bupropion.</p><p dir="ltr"><em>Treatment discontinuation</em></p><p dir="ltr">The treatment discontinuation rate due to adverse reactions was 11.4% for varenicline compared with 9.7% for placebo. In this group, the discontinuation rates for the most common adverse reactions in varenicline treated patients were as follows: nausea (2.7% vs. 0.6% for placebo), headache (0.6% vs. 1.0% for placebo), insomnia (1.3% vs. 1.2% for placebo), and abnormal dreams (0.2% vs. 0.2% for placebo).</p><p dir="ltr">Analyses of Clinical Trials:</p><p dir="ltr">A meta-analysis of 5 randomised, double-blind, placebo controlled trials, including 1907 patients (1130 varenicline, 777 placebo), was conducted to assess suicidal ideation and behaviour as reported on the Columbia-Suicide Severity Rating Scale (C-SSRS). This meta-analysis included one trial (N=127) in patients with a history of schizophrenia or schizoaffective disorder and another trial (N=525) in patients with a history of depression. The results showed no increase in the incidence of suicidal ideation and/or behaviour in patients treated with varenicline compared to patients treated with placebo, as shown in the table below. Of the 55 patients who reported suicidal ideation or behaviour, 48 (24 varenicline, 24 placebo) were from the two trials that enrolled patients with a history of schizophrenia/ schizoaffective disorder, or of depression. Few patients reported these events in the other three trials (4 varenicline, 3 placebo).</p><p dir="ltr"><strong>Number of Patients and Risk Ratio for Suicidal Ideation and/or Behaviour Reported on C-SSRS from a Meta- Analysis of 5 Clinical Trials Comparing Varenicline to Placebo:</strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:1016px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Varenicline</strong></p><p>(N=1130)</p></td><td style="vertical-align:top; width:466px"><p><strong>Placebo</strong></p><p>(N=777)</p></td></tr><tr><td style="vertical-align:top"><p>Patients with suicidal ideation and/or behaviour* [n (%)]**</p></td><td style="vertical-align:top"><p>28 (2.5)</p></td><td style="vertical-align:top; width:466px"><p>27 (3.5)</p></td></tr><tr><td style="vertical-align:top"><p>Patient-years of exposure</p></td><td style="vertical-align:top"><p>325</p></td><td style="vertical-align:top; width:466px"><p>217</p></td></tr><tr><td style="vertical-align:top"><p>Risk Ratio # (RR; 95% CI)</p></td><td colspan="2" style="vertical-align:top; width:572px"><p>0.79 (0.46, 1.36)</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:1013px"><p>* Of these, one patient in each treatment arm reported suicidal behaviour</p><p>** Patients with events up to 30 days after treatment; % are not weighted by study</p><p># RR of incidence rates per 100 patient years</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">A meta-analysis of 18 double-blind, randomised, placebo-controlled clinical trials was conducted to assess the neuropsychiatric safety of varenicline. These trials included the 5 trials described above that used the C-SSRS, and a total of 8521 patients (5072 varenicline, 3449 placebo), some of which had psychiatric conditions. The results showed a similar incidence of combined neuropsychiatric adverse events, other than sleep disorders, in patients treated with varenicline compared to patients treated with placebo, with a risk ratio (RR) of 1.01 (95% CI: 0.89-1.15). Pooled data from these 18 trials showed a similar incidence rate of individual categories of psychiatric events in patients treated with varenicline compared to patients treated with placebo. The table below describes the most frequently (&ge; 1%) reported categories of adverse events related to psychiatric safety other than sleep disorders and disturbances.</p><p dir="ltr"><strong>Psychiatric Adverse Events Occurring in &ge; 1% of Patients from Pooled Data from 18 Clinical Trials:</strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:1021px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Varenicline</strong></p><p>(N=5072)</p></td><td style="vertical-align:top; width:575px"><p><strong>Placebo</strong></p><p>(N=3449)</p></td></tr><tr><td style="vertical-align:top"><p>Anxiety disorders and symptoms</p></td><td style="vertical-align:top"><p>253 (5.0)</p></td><td style="vertical-align:top; width:575px"><p>206 (6.0)</p></td></tr><tr><td style="vertical-align:top"><p>Depressed mood disorders and disturbances</p></td><td style="vertical-align:top"><p>179 (3.5)</p></td><td style="vertical-align:top; width:575px"><p>108 (3.1)</p></td></tr><tr><td style="vertical-align:top"><p>Mood disorders and disturbances NEC*</p></td><td style="vertical-align:top"><p>116 (2.3)</p></td><td style="vertical-align:top; width:575px"><p>53 (1.5)</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:1018px"><p>* NEC = Not Elsewhere Classified</p><p>Counts (percentages) corresponds to the number of patients reporting the event</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">Observational Studies</p><p dir="ltr">Four observational studies, each including 10,000 to 30,000 users of varenicline in the adjusted analyses, compared the risk of serious neuropsychiatric events, including neuropsychiatric hospitalizations and fatal and non-fatal self-harm, in patients treated with varenicline versus patients prescribed NRT or bupropion. All studies were retrospective cohort studies and included patients with and without a psychiatric history. All studies used statistical methods to control for confounding factors, including preferential prescribing of varenicline to healthier patients, although there is the possibility of residual confounding.</p><p dir="ltr">Two of the studies found no difference in risk of neuropsychiatric hospitalisations between varenicline users and nicotine patch users (Hazard Ratio [HR] 1.14; 95% Confidence Interval [CI]: 0.56&ndash;2.34 in the first study, and 0.76; 95% CI: 0.40-1.46 in the second study). The power to detect differences in these two studies was limited. The third study reported no difference in risk of psychiatric adverse events diagnosed during an emergency department visit or inpatient admission between varenicline users and bupropion users (HR 0.85; 95% CI: 0.55-1.30). Based on post marketing reports, bupropion may be associated with neuropsychiatric adverse events.</p><p dir="ltr">The fourth study showed no evidence of a higher risk of fatal and non-fatal self- harm (HR of 0.88; 95% CI: 0.52-1.49) in patients prescribed varenicline compared to patients prescribed NRT. The occurrence of detected suicide was rare during the three months after patients initiated any drug treatment (two cases in 31,260 varenicline users and six cases in 81,545 NRT users).</p><p dir="ltr">Pregnancy Cohort Study</p><p dir="ltr">A population-based cohort study compared infants exposed to varenicline in utero (N=335) with infants born to mothers who smoked during pregnancy (N=78,412) and infants born to non-smoking mothers (N=806,438). In this study, infants exposed to varenicline in utero as compared to infants born to mothers who smoked during pregnancy had lower rates of congenital malformations (3.6% vs 4.3%), stillbirth (0.3% vs 0.5%), preterm birth (7.5% vs 7.9%), small for gestational age (12.5% vs 17.1%), and premature rupture of membrane (3.6% vs 5.4%). Paediatric Population</p><p dir="ltr">The efficacy and safety of varenicline was evaluated in a randomised, double-blind, placebo-controlled study of 312 patients aged 12 to 19 years, who smoked an average of at least 5 cigarettes per day during the 30 days prior to recruitment, and had a score of at least 4 on the Fagerstrom Test for Nicotine Dependence scale. Patients were stratified by age (12-16 years of age and 17-19 years of age) and by body weight (&le;55 kg and &gt;55 kg). Following two-week titration, patients randomised to varenicline with a body weight &gt;55 kg received 1 mg twice daily (high dose group) or 0.5 mg twice daily (low dose group), while patients with a body weight &le;55 kg received 0.5 mg twice daily (high dose group) or 0.5 mg once daily (low dose group). Patients received treatment for 12 weeks, followed by a non-treatment period of 40 weeks, along with age-appropriate counseling throughout the study.</p><p dir="ltr">The following table from the above paediatric study shows a comparison of continuous abstinence rates (CAR) from weeks 9-12, confirmed by urine cotinine test, for the full analysis set overall study population and the 12-17 year old population.</p><table border="1" cellspacing="0" cellpadding="0" style="width:1021px"><tbody><tr><td><p dir="ltr"><strong>CAR 9-12 (%)</strong></p></td><td><p dir="ltr"><strong>Overall</strong> <strong>n/N (%)</strong></p></td><td style="width:594px"><p dir="ltr"><strong>12-to-17-Year</strong><strong> </strong><strong>Olds</strong></p><p dir="ltr"><strong>n/N (%)</strong></p></td></tr><tr><td><p dir="ltr">High-Dose Varenicline</p></td><td><p dir="ltr">22/109 (20.2%)</p></td><td style="width:594px"><p dir="ltr">15/80 (18.8%)</p></td></tr><tr><td><p dir="ltr">Low-Dose Varenicline</p></td><td><p dir="ltr">28/103 (27.2%)</p></td><td style="width:594px"><p dir="ltr">25/78 (32.1%)</p></td></tr><tr><td><p dir="ltr">Placebo</p></td><td><p dir="ltr">18/100 (18.0%)</p></td><td style="width:594px"><p dir="ltr">13/76 (17.1%)</p></td></tr><tr><td><p dir="ltr"><strong>Treatment</strong><strong> </strong><strong>Comparisons</strong></p></td><td colspan="2" style="width:777px"><p dir="ltr"><strong>&nbsp;Odds ratio in CAR 9-12 (95% CI) [p-value]</strong></p></td></tr><tr><td><p dir="ltr">High-Dose Varenicline vs Placebo</p></td><td><p dir="ltr">1.18 (0.59, 2.37) [0.6337]</p></td><td style="width:594px"><p dir="ltr">1.13 (0.50, 2.56) [0.7753]</p></td></tr><tr><td><p dir="ltr">Low-Dose Varenicline vs Placebo</p></td><td><p dir="ltr">&nbsp; 1.73 (0.88, 3.39) [0.1114]</p></td><td style="width:594px"><p dir="ltr">&nbsp;&nbsp;2.28 (1.06, 4.89) [0.0347]*</p></td></tr><tr><td colspan="3" style="width:1018px"><p dir="ltr"><em>* This p value is not considered statistically significant. The prespecified statistical testing procedures stopped testing after the high-dose varenicline vs Placebo treatment comparison in the overall study did not achieve statistical significance.</em></p><p dir="ltr"><em>CI=confidence interval; N=number of subjects randomised; n=the number of subjects who, at each visit from weeks 9 to 12 (inclusive), reported no smoking and no use of other nicotine-containing products since the last study visit/last contact (on the Nicotine Use Inventory) and at any of these visits were confirmed to have quit based on urine cotinine test.</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Absorption</u></p><p dir="ltr">Maximum plasma concentrations of varenicline occur typically within 3-4 hours after oral administration. Following administration of multiple oral doses to healthy volunteers, steady-state conditions were reached within 4 days.</p><p dir="ltr">Absorption is virtually complete after oral administration and systemic availability is high. Oral bioavailability of varenicline is unaffected by food or time-of-day dosing.</p><p dir="ltr"><u>Distribution</u></p><p dir="ltr">Varenicline distributes into tissues, including the brain. Apparent volume of distribution averaged 415 litres (%CV= 50) at steady-state. Plasma protein binding of varenicline is low (&le; 20%) and independent of both age and renal function. In rodents, varenicline is transferred through the placenta and excreted in milk.</p><p dir="ltr"><u>Biotransformation</u></p><p dir="ltr">Varenicline undergoes minimal metabolism with 92% excreted unchanged in the urine and less than 10% excreted as metabolites. Minor metabolites in urine include varenicline N-carbamoylglucuronide and hydroxyvarenicline. In circulation, varenicline comprises 91% of drug-related material. Minor circulating metabolites include varenicline N- carbamoylglucuronide and N-glucosylvarenicline.</p><p dir="ltr"><em>In vitro</em> studies demonstrate that varenicline does not inhibit cytochrome P450 enzymes (IC50 &gt; 6,400 ng/ml). The P450 enzymes tested for inhibition were: 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5. Also, in human hepatocytes <em>in vitro</em>, varenicline was shown to not induce the activity of cytochrome P450 enzymes 1A2 and 3A4. Therefore, varenicline is unlikely to alter the pharmacokinetics of compounds that are primarily metabolised by cytochrome P450 enzymes.</p><p dir="ltr"><u>Elimination</u></p><p dir="ltr">The elimination half-life of varenicline is approximately 24 hours. Renal elimination of varenicline is primarily through glomerular filtration along with active tubular secretion via the organic cationic transporter, OCT2 (see section 4.5).</p><p dir="ltr"><u>Linearity/Non linearity</u></p><p dir="ltr">Varenicline exhibits linear kinetics when given as single (0.1 to 3 mg) or repeated 1 to 3 mg/day doses.</p><p dir="ltr"><u>Pharmacokinetics in special patient populations</u></p><p dir="ltr">There are no clinically meaningful differences in varenicline pharmacokinetics due to age, race, gender, smoking status, or use of concomitant medicinal products, as demonstrated in specific pharmacokinetic studies and in population pharmacokinetic analyses.</p><p dir="ltr"><em>Hepatic impairment</em></p><p dir="ltr">Due to the absence of significant hepatic metabolism, varenicline pharmacokinetics should be unaffected in patients with hepatic impairment. (see section 4.2).</p><p dir="ltr"><em>Renal impairment</em></p><p dir="ltr">Varenicline pharmacokinetics were unchanged in subjects with mild renal impairment (estimated creatinine clearance &gt; 50 ml/min and &le; 80 ml/min). In patients with moderate renal impairment (estimated creatinine clearance &ge; 30 ml/min and &le; 50 ml/min), varenicline exposure increased 1.5-fold compared with subjects with normal renal function (estimated creatinine clearance &gt; 80 ml/min). In subjects with severe renal impairment (estimated creatinine clearance &lt; 30 ml/min), varenicline exposure was increased 2.1-fold. In subjects with end-stage-renal disease (ESRD), varenicline was efficiently removed by haemodialysis (see section 4.2).</p><p dir="ltr"><em>Elderly</em></p><p dir="ltr">The pharmacokinetics of varenicline in elderly patients with normal renal function (aged 65-75 years) is similar to that of younger adult subjects (see section 4.2). For elderly patients with reduced renal function please refer to section 4.2.</p><p dir="ltr"><em>Paediatric population</em></p><p dir="ltr">Single and multiple-dose pharmacokinetics of varenicline have been investigated in paediatric patients aged 12 to 17 years old (inclusive) and were approximately dose-proportional over the 0.5 mg to 2 mg daily dose range studied.</p><p dir="ltr">Steady-state systemic exposure in adolescent patients of bodyweight &gt; 55 kg, as assessed by AUC (0-24), was comparable to that noted for the same doses in the adult population. When 0.5 mg twice daily was given, steady-state daily exposure of varenicline was, on average, higher (by approximately 40%) in adolescent patients with bodyweight &le; 55 kg compared to that noted in the adult population. Varenicline is not recommended in paediatric patients because its efficacy in this population was not demonstrated (see sections 4.2 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, fertility and embryo-foetal development. In male rats dosed for 2 years with varenicline, there was a dose-related increase in the incidence of hibernoma (tumour of the brown fat). In the offspring of pregnant rats treated with varenicline there were decreases in fertility and increases in the auditory startle response (see section 4.6). These effects were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use. Nonclinical data indicate varenicline has reinforcing properties albeit with lower potency than nicotine. In clinical studies in humans, varenicline showed low abuse potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><em>Tablet core:</em> Cellulose, Microcrystalline (PH-101), Cellulose, Microcrystalline (PH-102), Calcium Hydrogen Phosphate Anhydrous, Croscarmellose Sodium, Silica Colloidal Anhydrous, Magnesium Stearate and Purified water.</p><p dir="ltr"><em>Tablet coating:</em></p><p dir="ltr">0.5 mg: Opadry Complete Film Coating System 03A58900 White material (RMO419) (contains Hypromellose 2910 E464 and Titanium Dioxide E171).</p><p dir="ltr">1 mg: Opadry Complete Film Coating System 03A505012 Blue (contains Hypromellose 2910 E464, Titanium Dioxide E171, FD&amp;C BLUE #2/Indigo carmine aluminum E132, FD&amp;C BLUE #2/Indigo carmine aluminum lake E132).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Varenicline Tablets are available in following Pack:</p><p dir="ltr">Varlin available in in clear PVC- Aluminium blister pack.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment initiation pack: 11 tablets x 0.5 mg (11&rsquo;s blister x 1) and 14 tablets x 1 mg (14&rsquo;s blister x 1).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Follow-on (maintenance) pack: 56 tablets x 1 mg (14&rsquo;s blister x 4)</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aurobindo Pharma Saudi Arabia Limited,
Jeddah, Saudi Arabia.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>